AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesDisciplines and OccupationsAnthropology, Education, Sociology and Social PhenomenaTechnology, Industry, AgricultureInformation ScienceHealth CareGeographicals
Hodgkin DiseaseReed-Sternberg CellsAntigens, CD30MechlorethamineProcarbazineBleomycinVinblastineDacarbazineAntigens, CD20Epstein-Barr Virus InfectionsVincristineLymphomaPrednisoneNeoplasms, Second PrimaryLymph NodesLymphoma, Large B-Cell, DiffuseLymphoma, Non-HodgkinDoxorubicinAntineoplastic Combined Chemotherapy ProtocolsLymphocytesCombined Modality TherapyB-LymphocytesImmunohistochemistrySurvival RateSurvival AnalysisTreatment OutcomeRetrospective StudiesPrognosisFollow-Up StudiesTumor Cells, CulturedTime FactorsHerpesvirus 4, HumanAsparaginaseBostonPrecursor Cell Lymphoblastic Leukemia-LymphomaNational Institute on Aging (U.S.)MedlinePlusGroinAnimal Identification SystemsElectronic MailFood Dispensers, AutomaticEditorial PoliciesAuthorshipPeriodicals as TopicPostal ServiceInternetLymphatic SystemLymphatic VesselsUrogenital NeoplasmsHypermediaAdaptation, PsychologicalResearchInformation SystemsMedical Oncology
Hodgkin Disease: A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.Reed-Sternberg Cells: Large cells, usually multinucleate, whose presence is a common histologic characteristic of classical HODGKIN DISEASE.Antigens, CD30: A member of the tumor necrosis factor receptor superfamily that may play a role in the regulation of NF-KAPPA B and APOPTOSIS. They are found on activated T-LYMPHOCYTES; B-LYMPHOCYTES; NEUTROPHILS; EOSINOPHILS; MAST CELLS and NK CELLS. Overexpression of CD30 antigen in hematopoietic malignancies make the antigen clinically useful as a biological tumor marker. Signaling of the receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.Mechlorethamine: A biologic alkylating agent that exerts its cytotoxic effects by forming DNA ADDUCTS and DNA interstrand crosslinks, thereby inhibiting rapidly proliferating cells. The hydrochloride is an antineoplastic agent used to treat HODGKIN DISEASE and LYMPHOMA.Procarbazine: An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.Bleomycin: A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors.Vinblastine: Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)Dacarbazine: An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564)Antigens, CD20: Unglycosylated phosphoproteins expressed only on B-cells. They are regulators of transmembrane Ca2+ conductance and thought to play a role in B-cell activation and proliferation.Epstein-Barr Virus Infections: Infection with human herpesvirus 4 (HERPESVIRUS 4, HUMAN); which may facilitate the development of various lymphoproliferative disorders. These include BURKITT LYMPHOMA (African type), INFECTIOUS MONONUCLEOSIS, and oral hairy leukoplakia (LEUKOPLAKIA, HAIRY).Vincristine: An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)Lymphoma: A general term for various neoplastic diseases of the lymphoid tissue.Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.Neoplasms, Second Primary: Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.Lymph Nodes: They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system.Lymphoma, Large B-Cell, Diffuse: Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.Lymphoma, Non-Hodgkin: Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.Doxorubicin: Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.Antineoplastic Combined Chemotherapy Protocols: The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.Lymphocytes: White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS.Combined Modality Therapy: The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.B-Lymphocytes: Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation.Immunohistochemistry: Histochemical localization of immunoreactive substances using labeled antibodies as reagents.Survival Rate: The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.Survival Analysis: A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Retrospective Studies: Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.Prognosis: A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.Follow-Up Studies: Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.Tumor Cells, Cultured: Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.Time Factors: Elements of limited time intervals, contributing to particular results or situations.Herpesvirus 4, Human: The type species of LYMPHOCRYPTOVIRUS, subfamily GAMMAHERPESVIRINAE, infecting B-cells in humans. It is thought to be the causative agent of INFECTIOUS MONONUCLEOSIS and is strongly associated with oral hairy leukoplakia (LEUKOPLAKIA, HAIRY;), BURKITT LYMPHOMA; and other malignancies.Asparaginase: A hydrolase enzyme that converts L-asparagine and water to L-aspartate and NH3. EC 3.5.1.1.BostonPrecursor Cell Lymphoblastic Leukemia-Lymphoma: A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.National Institute on Aging (U.S.): Component of the NATIONAL INSTITUTES OF HEALTH. Through basic and clinical biomedical research and training, it conducts and supports research into the nature of the aging process and diseases associated with the later stages of life. The Institute was established in 1974.MedlinePlus: NATIONAL LIBRARY OF MEDICINE service for health professionals and consumers. It links extensive information from the National Institutes of Health and other reviewed sources of information on specific diseases and conditions.Groin: The external junctural region between the lower part of the abdomen and the thigh.Animal Identification Systems: Procedures for recognizing individual animals and certain identifiable characteristics pertaining to them; includes computerized methods, ear tags, etc.Electronic Mail: Messages between computer users via COMPUTER COMMUNICATION NETWORKS. This feature duplicates most of the features of paper mail, such as forwarding, multiple copies, and attachments of images and other file types, but with a speed advantage. The term also refers to an individual message sent in this way.Food Dispensers, Automatic: Mechanical food dispensing machines.Editorial Policies: The guidelines and policy statements set forth by the editor(s) or editorial board of a publication.Authorship: The profession of writing. Also the identity of the writer as the creator of a literary production.Periodicals as Topic: A publication issued at stated, more or less regular, intervals.Postal Service: The functions and activities carried out by the U.S. Postal Service, foreign postal services, and private postal services such as Federal Express.Internet: A loose confederation of computer communication networks around the world. The networks that make up the Internet are connected through several backbone networks. The Internet grew out of the US Government ARPAnet project and was designed to facilitate information exchange.Lymphatic System: A system of organs and tissues that process and transport immune cells and LYMPH.Lymphatic Vessels: Tubular vessels that are involved in the transport of LYMPH and LYMPHOCYTES.Urogenital Neoplasms: Tumors or cancer of the UROGENITAL SYSTEM in either the male or the female.Hypermedia: Computerized compilations of information units (text, sound, graphics, and/or video) interconnected by logical nonlinear linkages that enable users to follow optimal paths through the material and also the systems used to create and display this information. (From Thesaurus of ERIC Descriptors, 1994)Adaptation, Psychological: A state of harmony between internal needs and external demands and the processes used in achieving this condition. (From APA Thesaurus of Psychological Index Terms, 8th ed)Research: Critical and exhaustive investigation or experimentation, having for its aim the discovery of new facts and their correct interpretation, the revision of accepted conclusions, theories, or laws in the light of newly discovered facts, or the practical application of such new or revised conclusions, theories, or laws. (Webster, 3d ed)Information Systems: Integrated set of files, procedures, and equipment for the storage, manipulation, and retrieval of information.Medical Oncology: A subspecialty of internal medicine concerned with the study of neoplasms.

Intensive investigation in management of Hodgkin's disease. (1/3116)

Ninety-eight patients with clinically localised Hodgkin's disease underwent laparotomy and splenectomy to determine the extent of microscopic spread. In 68 patients the procedure was carried out for untreated disease apparently confined above the diaphragm. Abdominal disease cannot be confidently excluded on the basis of non-invasive investigation at presentation. Clinical assessment of splenic disease was unreliable unless gross splenomegaly was present. Pedal lymphography was accurate in assessing para-aortic and iliac disease but of no value in assessing other intra-abdominal lymph node involvement, including that of the mesenteric lymph node. Trephine bone marrow biopsy findings were normal in all patients before surgery, and only one patient was found to have diseased bone marrow by Stryker-saw biopsy at operation. Liver disease was identified at operation in nine patients, some of whom were asymptomatic with clinically undetectable splenic and nodal disease. Detailed clinical staging failed to detect disease in one-third of patients who underwent laparotomy. These studies show that if radiotherapy is to remain the treatment of choice for disease truly localised to lymph nodes a detailed staging procedure, including laparotomy and splenectomy, remains essential. The value of this potentially curative treatment is considerably diminished in the patient who has been inadequately staged.  (+info)

Prednisone in MOPP chemotherapy for Hodgkin's disease. (2/3116)

High remission rates have been produced by MOPP (mustine, vincristine, procarbazine, and prednisone) chemotherapy in patients with advanced Hodgkin's disease, but the prednisone component has caused adverse effects in patients who have undergone radiotherapy. The remission rates and length of remission were reviewed in 211 patients with Hodgkin's disease who received chemotherapy either with or without prednisone. In contrast to the findings of a British study, there were no significant differences in remission rates or length of remission between patients who had received prednisone and patients who had not. There were differences between the British prospective study and this retrospective one, but it is difficult to know what accounted for the substantial differences in the findings.  (+info)

Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. (3/3116)

PURPOSE: Recent studies have suggested that lymphocyte-predominant Hodgkin's disease (LPHD) is both clinically and pathologically distinct from other forms of Hodgkin's disease, including classical Hodgkin's disease (CHD). However, large-scale clinical studies were lacking. This multicenter, retrospective study investigated the clinical characteristics and course of LPHD patients and lymphocyte-rich classical Hodgkin's disease (LRCHD) patients classified according to morphologic and immunophenotypic criteria. MATERIALS AND METHODS: Clinical data and biopsy material of all available cases initially submitted as LPHD were collected from 17 European and American centers, stained, and reclassified by expert pathologists. RESULTS: The 426 assessable cases were reclassified as LPHD (51%), LRCHD (27%), CHD (5%), non-Hodgkin's lymphoma (3%), and reactive lesion (3%); 11% of cases were not assessable. Patients with LPHD and LRCHD were predominantly male, with early-stage disease and few risk factors. Patients with LRCHD were significantly older. Survival and failure-free survival rates with adequate therapy were similar for patients with LPHD and LRCHD, and were stage-dependent and not significantly better than stage-comparable results for CHD (German trial data). Twenty-seven percent of relapsing LPHD patients had multiple relapses, which is significantly more than the 5% of relapsing LRCHD patients who had multiple relapses. Lymphocyte-predominant Hodgkin's disease patients had significantly superior survival after relapse compared with LRCHD or CHD patients; however, this was partly due to the younger average age of LPHD patients. CONCLUSION: The two subgroups of LPHD and LRCHD bore a close clinical resemblance that was distinct from CHD; the course was similar to that of comparable nodular sclerosis and mixed cellularity patients. Thorough staging is necessary to detect advanced disease in LPHD and LRCHD patients. The question of how to treat such patients, either by reducing treatment intensity or following a "watch and wait" approach, remains unanswered.  (+info)

Autologous hematopoietic stem-cell transplantation for relapsed or refractory Hodgkin's disease in children and adolescents. (4/3116)

PURPOSE: To determine the treatment outcome and clinical factors that are of prognostic significance for children and adolescents with relapsed or refractory Hodgkin's disease (HD) who received treatment with high-dose chemotherapy and autologous hematopoietic stem-cell transplantation (HSCT). PATIENTS AND METHODS: Fifty-three consecutive children and adolescents 21 years of age or younger with relapsed or refractory HD underwent HSCT. RESULTS: At day 100 after transplantation, 29 patients (55%) were in a complete remission or maintained a continuous complete response, six (11%) had a partial response, and 11 (21%) failed to respond or had progressive disease. The failure-free survival (FFS) at 5 years was 31%, and overall survival was 43%. Twenty-one patients died of progressive HD, and nine died secondary to transplantation-related complications, including two secondary leukemias. Prognostic factors important for FFS were normal pretransplantation lactate dehydrogenase levels (5-year FFS = 42%), compared with patients with elevated LDH levels (5-year FFS = 0%) (P < .001), and disease sensitivity at the time of HSCT with FFS in untreated relapse, sensitive disease, and resistant disease 44%, 35%, and 9%, respectively (P = .06). There was no statistically significant difference in FFS or overall survival between age subgroups that were analyzed (< 13, 13 to 18, 19 to 21) or in comparison with an adult cohort. CONCLUSION: HSCT is an effective treatment modality that can result in long-term cures and should be considered for children and adolescents with relapsed HD.  (+info)

Reduced health-related quality of life among Hodgkin's disease survivors: a comparative study with general population norms. (5/3116)

BACKGROUND: Late complications after curative treatment of Hodgkin's disease are of special relevance because most of the cured are young adults. The aims of the present study were: (1) to compare health-related quality of life (HRQOL) in Hodgkin's disease (HD) survivors with normative data from the general Norwegian population and (2) to examine the relations between disease/treatment characteristics and HRQOL in the HD survivors. PATIENTS AND METHODS: 459 HD survivors aged 19-74 years (mean 44.0, SD 11.8) treated at the Norwegian Radium Hospital 1971-1991 were approached in 1994 and compared to norms from 2214 subjects approached in 1996. The norms are representative of the general Norwegian population. HRQOL was assessed by the Short Form 36 (SF-36), which measures HRQOL in eight separate scales (0 = worst health state, 100 = best health state). RESULTS: The HD survivors had lower scores than the normal controls on all scales after adjustment for age, gender and educational levels. Statistically significant differences (P < 0.01) were found in general health (10.4), physical functioning (6.1), role limitations (physical, 9.3), physical functioning (3.6) and in vitality (4.7). Patients with disease stage IB-IIB had the lowest scores on all scales. The differences in relation to stage/substage reached statistical significance (P < 0.01) in physical functioning and in role limitations (physical). Time since diagnosis, types of primary treatment or having relapsed were not associated with statistically significant differences in HRQOL. CONCLUSION: Long-term HD survivors have poorer HRQOL, primarily in physical health, than the general Norwegian population.  (+info)

Bone marrow scintigraphy using technetium-99m antigranulocyte antibody in malignant lymphomas. (6/3116)

BACKGROUND: The purpose of this study was to elucidate the clinical reliability of immunoscintigraphy (IS) to detect infiltration of the bone marrow in patients with malignant lymphoma. PATIENTS AND METHODS: Whole body IS was performed in 103 patients with Hodgkin's disease (HD) or non-Hodgkin's lymphoma (NHL) using Tc-99m labelled anti-NCA-95 which allows visualization of the granulopoietic bone marrow. Of these, 52% were studied prior to any therapy. Findings were compared to posterior iliac crest biopsy as well as MRI and/or follow-up examination. Criteria of marrow infiltration were a positive biopsy, positive follow-up, or positive results of MRI. RESULTS: Comparison of IS and biospy revealed concordant findings in 69 and discordant findings in 34 of 103 patients. Of the 34 patients with discordant results, IS showed lesions suspicious of bone marrow infiltration in 29 patients despite normal biopsy findings. When follow-up and additional examinations were taken into consideration, 10 patients remained with probably false positive and five with false negative IS findings. IS proved to be highly sensitive and specific in patients with HD (100% and 84%, respectively) and high-grade NHL (93% and 84%, respectively). Moderate sensitivity (60%) was found in low-grade NHL. This was possibly due to false negative IS in three to five patients with chemotherapy in contrast to one of five false negative results in patients without chemotherapy. CONCLUSION: Bone marrow scintigraphy using antigranulocyte antibodies is highly sensitive in HD and high-grade NHL. Positive findings in IS subsequent to a negative biopsy should be followed by guided re-biopsy or MRI.  (+info)

Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. (7/3116)

PURPOSE: Hodgkin's disease patients who never achieve complete remission with conventional chemotherapy (i.e., those with primary induction failure) have a poor prognosis. Some subjects who receive high-dose therapy with autologous hematopoietic progenitor-cell infusion experience prolonged progression-free survival. PATIENTS AND METHODS: Detailed records from the Autologous Blood and Marrow Transplant Registry (ABMTR) on 122 Hodgkin's disease patients who failed to achieve complete remission after one or more conventional therapy regimens and subsequently received an autotransplant between 1989 and 1995 were reviewed. RESULTS: Median age was 27 years (range, 7 to 57 years). Median time from diagnosis to transplantation was 14 months (range, 5 to 38 months). Most patients received high-dose chemotherapy without radiation for pretransplantation conditioning (n = 107). The regimen most frequently used was cyclophosphamide, carmustine, and etoposide (n = 47). Fifteen patients received total-body irradiation (n = 15). The graft consisted of bone marrow (n = 86), blood stem cells (n = 25), or both (n = 11). The 100-day mortality was 12% (95% confidence interval, 7% to 19%). Sixty patients (50%) were considered to have achieved complete remission after autotransplantation; 37 of these had negative imaging studies, whereas scan abnormalities of unknown significance persisted in 23 patients. Twenty-seven patients (22%) had no response or progressive disease after transplantation. Probabilities of progression-free and overall survival at 3 years were 38% (95% confidence interval, 28% to 48%) and 50% (95% confidence interval, 39% to 60%), respectively. In multivariate analysis, "B" symptoms at diagnosis and poor performance score at transplantation were adverse prognostic factors for outcome. CONCLUSION: Autotransplants should be considered for patients with Hodgkin's disease who do not achieve complete remission with conventional therapy.  (+info)

Stimulation of autologous blood lymphocytes by malignant lymphoma cells and homogenates. (8/3116)

The blastogenic response to autologous blood lymphocytes to whole-cell suspensions and to homogenates obtained from malignant lymphoma tissue has been investigated. Spleens were obtained from patients in whom laparotomy was performed for staging of malignant lymphoma. Cell suspensions prepared from tumour nodules were treated with mitomycin C and allowed to react with separated autologous blood lymphocytes for 6 days. Lymphocyte stimulation was measured by liquid scintillation counting after exposure to 3H-TdR. Cultures were also prepared in which autologous lymphocytes were treated with spleen tumour homogenate. Control experiments used spleens from staging procedures in which no tumour deposits were present, and normal spleens removed incidentally during other operations. In the controls, the uptake of TdR was never more than twice that of unstimulated lymphocytes. Greater degrees of lymphocyte stimulation were seen in 6 out of 14 patients, using whole tumour cells, and in 7 out of 16 patients, using tumour homogenates. The results indicate an antigenic difference between tumour and host cells, and suggest that lymphocytes can react to a tumour-associated antigen.  (+info)

Nodular lymphocyte predominant Hodgkin lymphoma in Sweden between 2000 and 2014 : An analysis of the Swedish Lymphoma RegistryNodular lymphocyte predominant Hodgkin lymphoma in Sweden between 2000 and 2014 : An analysis of the Swedish Lymphoma Registry
article{f1d460a6-1694-4cd3-a657-b01df9443c91, abstract = {,p,Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is an indolent CD20,sup,+,/sup, lymphoma. Its scarcity has made clinical trials difficult and there is no consensus on first-line treatment. We conducted a population-based study of all patients diagnosed with NLPHL in Sweden between 2000 and 2014 (N = 158; 41 women and 117 men), focusing on clinical features, therapy and overall survival. The median female and male age was 59 and 44 years, respectively (P = 0·002). In early-stage disease, there was little mortality and no survival differences between therapies. In patients with advanced-stage disease, mortality was relatively high in patients who did not receive first-line rituximab but absent in those who did (10-year survival, 55% vs. 100%; P = 0·033); there were no imbalances of prognostic factors between those two groups. In advanced stages, first-line rituximab use increased markedly between 2000-2004 and 2005-2014 (7% vs. ...
Treatment of nodular lymphocyte-predominant Hodgkin lymphomaTreatment of nodular lymphocyte-predominant Hodgkin lymphoma
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is an uncommon subtype of Hodgkin lymphoma (HL). This disorder is differentiated from all other forms of HL, which are commonly referred to as classical Hodgkin lymphomas (cHLs), by characterist
TJMayer - Patient: Hodgkin Disease | Nodular lymphocyte predominant Hodgkin disease - Living with cancer as a chronic illness ...TJMayer - Patient: Hodgkin Disease | Nodular lymphocyte predominant Hodgkin disease - Living with cancer as a chronic illness ...
TJMayer - Patient: Hodgkin Disease > Nodular lymphocyte predominant Hodgkin disease Patient Info: Living with cancer as a chronic illness (undergoing adjuvant therapy), Diagnosed: almost 11 years ago, Male, Age: 61, Stage III
ICD-10 Diagnosis Code C81.0 Nodular lymphocyte predominant Hodgkin lymphomaICD-10 Diagnosis Code C81.0 Nodular lymphocyte predominant Hodgkin lymphoma
Diagnosis Code C81.0 information, including descriptions, synonyms, code edits, diagnostic related groups, ICD-9 conversion and references to the diseases index.
ICD-10-CM Code C81.00 - Nodular lymphocyte predominant Hodgkin lymphoma, unspecified siteICD-10-CM Code C81.00 - Nodular lymphocyte predominant Hodgkin lymphoma, unspecified site
This is the official approximate match mapping between ICD9 and ICD10, as provided by the General Equivalency mapping crosswalk. This means that while there is no exact mapping between this ICD10 code C81.00 and a single ICD9 code, 201.40 is an approximate match for comparison and conversion purposes. ...
Lymphoma Action | Nodular lymphocyte-predominant Hodgkin lymphomaLymphoma Action | Nodular lymphocyte-predominant Hodgkin lymphoma
Quick overview of NLPHL This section is an overview of the information on this page. There is more detail in the sections below. What is it? NLPHL is a rare, slow-growing type of lymphoma. It is a type of cancer where the abnormal cells are lymphocytes (a type of white blood cell).
Nodular lymphocyte predominant Hodgkins lymphoma - WikipediaNodular lymphocyte predominant Hodgkin's lymphoma - Wikipedia
Nodular lymphocyte predominant Hodgkins lymphoma (NLPHL) is an indolent CD20(+) form of lymphoma. Some people no longer classified it as a form of classic Hodgkins lymphoma (HL). This is because the Reed-Sternberg cell (RSC) variants (popcorn cells) that characterize this form of the disease invariably express B lymphocyte markers such as CD20 (thus making NLPHL an unusual form of B cell lymphoma), and that (unlike classic HL) NLPHL may progress to diffuse large B cell lymphoma. There are small but clear differences in prognosis between the various forms. Lymphocyte predominant HL is an uncommon subtype composed of vague nodules of numerous reactive lymphocytes admixed with large popcorn-shaped RSC. Unlike classic RSC, the non-classic popcorn-shaped RS cells of NLPHL are CD15 and CD30 negative while positive for the B cell marker CD20. The anti-CD20 monoclonal antibody Rituximab has been used in lymphocyte predominant Hodgkins lymphoma with encouraging results. BCL6 gene rearrangements have ...
Most recent papers with the keyword Lymphoma | Read by QxMDMost recent papers with the keyword Lymphoma | Read by QxMD
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare lymphoma entity with an incidence of 0.1 to 0.2/100 000/y. Compared with the more common subtypes of classical Hodgkin lymphoma, NLPHL is characterized by distinct pathological and clinical features. Histologically, the disease-defining lymphocyte predominant cells consistently express CD20 but lack CD30. Clinically, NLPHL mostly has a rather indolent course, and patients usually are diagnosed in early stages. The prognosis of early-stage NLPHL is excellent, with progression-free survival and overall survival rates exceeding 90% after involved-field radiotherapy (IF-RT) alone (stage IA) or combined modality treatment consisting of a brief chemotherapy with 2 cycles of ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) chemotherapy followed by IF-RT (early stages other than stage IA ...
Utility of Routine Surveillance Laboratory Testing in Detecting Relapse in Patients With Classic Hodgkin Lymphoma in First...Utility of Routine Surveillance Laboratory Testing in Detecting Relapse in Patients With Classic Hodgkin Lymphoma in First...
PURPOSE: Classic Hodgkin lymphoma is highly curable with contemporary therapy. Although the limited role of surveillance imaging to detect early relapse for patients in complete remission at the end of therapy is well established, there is a paucity of data regarding role of laboratory testing in this setting.. METHODS: Patients with newly diagnosed classic Hodgkin lymphoma uniformly treated with the Stanford V regimen from 1998-2014 and in complete remission for at least 3 months were identified in a single-center institutional database. Laboratory tests categorized by Common Terminology Criteria for Adverse Events v4.03 as grade 2 or higher were considered abnormal. Primary analysis included sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of surveillance laboratory tests for predicting relapse in the first 3 years after end of treatment.. RESULTS: Among 235 eligible patients, 24 (10.2%) patients ultimately relapsed. In the first 3 years after end ...
OPUS 4 | SearchOPUS 4 | Search
Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is an indolent lymphoma, but can transform into diffuse large B cell lymphoma (DLBCL), showing a more aggressive clinical behavior. Little is known about these cases on the molecular level. Therefore, the aim of the present study was to characterize DLBCL transformed from NLPHL (LP-DLBCL) by gene expression profiling (GEP). GEP revealed an inflammatory signature pinpointing to a specific host response. In a coculture model resembling this host response, DEV tumor cells showed an impaired growth behavior. Mechanisms involved in the reduced tumor cell proliferation included a downregulation of MYC and its target genes. Lack of MYC expression was also confirmed in 12/16 LP-DLBCL by immunohistochemistry. Furthermore, CD274/PD-L1 was upregulated in DEV tumor cells after coculture with T cells or monocytes and its expression was validated in 12/19 cases of LP-DLBCL. Thereby, our data provide new insights into the pathogenesis of LP-DLBCL and an ...
steveo - Survivor: Hodgkin Disease | Classic Hodgkin Disease | Nodular sclerosing - Finished active treatment more than 5 years...steveo - Survivor: Hodgkin Disease | Classic Hodgkin Disease | Nodular sclerosing - Finished active treatment more than 5 years...
steveo - Survivor: Hodgkin Disease > Classic Hodgkin Disease > Nodular sclerosing Patient Info: Finished active treatment more than 5 years ago, Diagnosed: almost 18 years ago, Male, Age: 32
KEYTRUDA® Superior to ADCETRIS® in Relapsed or Refractory Classical Hodgkin Lymphoma - OncoPrescribeKEYTRUDA® Superior to ADCETRIS® in Relapsed or Refractory Classical Hodgkin Lymphoma - OncoPrescribe
Preclinical studies suggest that HRS cells evade immune detection by exploiting the pathways associated with immune checkpoint, Programmed Death-1 (PD-1) and its ligands PD-L. Classical Hodgkin Lymphoma is an excellent example of how the tumor microenvironment influences cancer cells to proliferate and survive. The most common genetic abnormality in Nodular sclerosis subtype of Hodgkin lymphoma is the selective amplification of genes on the short arm of chromosome 9 (9p24.1) which includes JAK-2, with resulting increased expression of PD-1 ligands such as PDL1 and PDL2 on HRS cells, as well as increased JAK-STAT activity, essential for the proliferation and survival of Hodgkin Reed-Sternberg (HRS) cells. Infection with Epstein-Barr virus (EBV) similarly can increase the expression of PDL1 and PDL2 in EBV-positive Hodgkin lymphomas. It would therefore seem logical to block or inhibit immune check point PD-1 rather than both its ligands, PDL1 and PDL2.. Immune checkpoints are cell surface ...
Hodgkin LymphomaHodgkin Lymphoma
... is cancer that begins in the lymph system in white blood cells called lymphocytes. When these cells become abnormal, they grow without control and may form lumps of tissue called tumors.. The most common type of Hodgkin lymphoma is called classical Hodgkin lymphoma. The cancerous tumors (lymphomas) in classical Hodgkin lymphoma contain Reed-Sternberg cells. Non-Hodgkin lymphomas dont have these cells.. Symptoms of Hodgkin lymphoma include enlargement of the lymph nodes, fever, appetite loss, weight loss, and night sweats.. Hodgkin lymphoma affects men more often than women. The cause of Hodgkin lymphoma is not known.. Treatment for Hodgkin lymphoma depends on the stage of the lymphoma and may include radiation or chemotherapy.. ...
Interventions for early stage Hodgkins disease in children: Cochrane systematic review | Cochrane AbstractsInterventions for early stage Hodgkin's disease in children: Cochrane systematic review | Cochrane Abstracts
Interventions for early stage Hodgkins disease in children: Cochrane systematic review answers are found in the Cochrane Abstracts powered by Unbound Medicine. Available for iPhone, iPad, Android, and Web.
QIMRS world-first discovery for Hodgkin lymphoma patients - QIMR BerghoferQIMR'S world-first discovery for Hodgkin lymphoma patients - QIMR Berghofer
Scientists at the Queensland Institute of Medical Research have discovered that a simple blood test can determine how well chemotherapy is working in Hodgkin lymphoma patients.. The discovery by Professor Maher Gandhi and Kimberley Jones from QIMRs Clinical Immunohaematology Laboratory could mean personalised treatment for patients with the blood cancer.. "This has the potential to be a huge aid for doctors in their decision making and a faster and less invasive process for the patients," Professor Gandhi said.. "Up until now, clinicians have relied on scans to help them judge how well people are responding to chemotherapy. The imaging is expensive, it can be difficult to interpret, and can be limited to just one scan before treatment starts, and another when treatment is finished.. "This discovery means we can work towards using simple blood tests to provide quicker, cheaper, and more regular monitoring of how a person is responding to treatment.". About 400 Australians are diagnosed with ...
New Drug Dramatically Improves Survival in Hodgkin Lymphoma PatientsNew Drug Dramatically Improves Survival in Hodgkin Lymphoma Patients
A new cancer drug with remarkably few side effects is dramatically improving survival in Hodgkin lymphoma patients who fail other treatments and are nearly out of options.
Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin s Lymphoma - Full Text View -...Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin s Lymphoma - Full Text View -...
2.1.1.1 All patients must have a pathologically confirmed diagnosis of classical Hodgkins lymphoma (HL) as outlined in the World Health Organization (WHO) Classification System of Lymphoid Tumours. Patients with nodular lymphocyte-predominant Hodgkins lymphoma (HL) (NLPHL) are not eligible.. 2.1.1.2 Refractory or relapsed HL patients that are also candidates for auto stem cell transplant (ASCT).. 2.1.1.3 At least one adverse prognostic factor: (1) initial relapse less than or equal to 12 months after primary chemotherapy, (2) staged as Ann Arbor Classification initial stage III or IV disease, (3) chemotherapy resistant disease, (4) Failure to achieve a complete response (CR) with cytoreductive chemotherapy or persistent positive (18) fluorodeoxyglucose positron emission tomography (FDGPET) imaging.. 2.1.1.4 At least 10% of the cells obtained from lymph node, or extranodal sites must react with anti-cluster of differentiation 25 (CD25) (anti-Tac) on immunofluorescent or immunoperoxidase ...
Cells which contain S-100 protein in Hodgkins disease: a quantitative study. | Journal of Clinical PathologyCells which contain S-100 protein in Hodgkin's disease: a quantitative study. | Journal of Clinical Pathology
Paraffin sections from a series of 50 lymph nodes affected by Hodgkins disease were examined by means of the unlabelled primary antibody peroxidase-antiperoxidase method to detect those cells which contained S-100 protein. In addition, 15 lymph nodes showing reactive follicular hyperplasia were studied. A simple enumeration procedure (eyepiece graticule) was used to count the number of such cells in 20 standard 25 X microscope fields. In the specimens of nodular sclerosing Hodgkins disease many cells positive for S-100 protein were present, in contrast to the other Rye subtypes, which showed a relative paucity. By comparison, the lymph nodes showing reactive follicular hyperplasia contained a similar number of cells containing S-100 to those seen in the nodular sclerosing lymph nodes affected by Hodgkins disease.. ...
Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease - Full Text View -...Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease - Full Text View -...
Patients receive doxorubicin hydrochloride 50 mg/m2 IV over 10-30 minutes and cyclophosphamide 800 mg/mg2 IV over 1 hour on day 1, vincristine sulfate 1.4 mg/m2 IV (2.8 mg maximum) over 1 minute on days 1 and 8, and prednisone 40 mg/m2/day PO or IV two or three times daily on days 1-7. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve CR after 3 courses of therapy proceed to follow-up. Patients who do not achieve a CR proceed to involved-field radiation therapy (IFRT).. IFRT: Beginning within 3 weeks after completion of combination chemotherapy, patients undergo IFRT once daily, 5 days a week for 2.8 weeks (14 treatments). ...
Post-Transplant Brentuximab Vedotin Improved Progression-Free Survival in Hodgkin Lymphoma Patients - The ASCO PostPost-Transplant Brentuximab Vedotin Improved Progression-Free Survival in Hodgkin Lymphoma Patients - The ASCO Post
In patients with Hodgkin lymphoma who are at risk for disease progression following autologous stem cell transplantation, early consolidation with brentuximab vedotin (Adcetris) post-transplant significantly improved progression-free survival compared with placebo in the phase III AETHERA trial.1 The median progression-free survival was 43 months for the brentuximab-treated group vs 24 months for the placebo group, representing a significant 43% reduction in the risk of disease progression (P = .001).. "In my opinion, once this study is published, brentuximab should be the standard of care for patients with the characteristics in this trial: that is, remission duration less than 1 year, extranodal disease, B symptoms, two or more prior salvage therapies, and primary refractory disease," said lead author Craig Moskowitz, MD, Clinical Director of the Division of Hematologic Oncology at Memorial Sloan Kettering Cancer Center, New York.. Dr. Moskowitz explained that autologous stem cell ...
Treatment plan improves survival for Hodgkin lymphoma patients - Canadian Cancer SocietyTreatment plan improves survival for Hodgkin lymphoma patients - Canadian Cancer Society
16 December 2011 Toronto - A Canadian-led clinical trial has found that patients with limited stage Hodgkin lymphoma have better overall survival rates when treated with chemotherapy compared with those receiving extensive radiation. The results were presented at the American Society of Hematology annual meeting and published online by The New England Journal of Medicine.. Currently, patients with limited stage Hodgkin lymphoma receive radiation therapy combined with chemotherapy. While this combination therapy is effective at controlling the disease, patients may experience long-term side effects, such as heart conditions or subsequent cancers, from the radiation. For this study, the researchers recruited 405 patients with limited stage (IA or IIA) Hodgkin lymphoma (HL). The trial participants were divided into favourable- and unfavourable-risk groups and randomized into two treatment arms: those who received the ABVD chemotherapy regimen and those who received radiation therapy (with or ...
ICD-10 Code: C81.73 - Oth classical Hodgkin lymphoma, intra-abdominal lymph nodesICD-10 Code: C81.73 - Oth classical Hodgkin lymphoma, intra-abdominal lymph nodes
The ICD-10 Code C81.73 is the code used for Oth classical Hodgkin lymphoma, intra-abdominal lymph nodes .An alternative description for this code is Other classical Hodgkin lymphoma, intra-abdominal ...
PET Scans Guiding Chemo Boosts Remission for Hodgkin Lymphoma PatientsPET Scans Guiding Chemo Boosts Remission for Hodgkin Lymphoma Patients
For people with advanced Hodgkin lymphoma, using PET imaging to guide chemotherapy treatment significantly increases the number of people who go into remission.
City of Hope-led research suggests brentuximab vedotin potentially curative in some Hodgkin lymphoma patients with limited...City of Hope-led research suggests brentuximab vedotin potentially curative in some Hodgkin lymphoma patients with limited...
City of Hope research-led study reports on five-year survival data, suggests that the targeted therapy brentuximab vedotin (BV) should be standard of care for patients with relapsed or treatment-resistant Hodgkin lymphoma.
Hodgkin Lymphoma Survivors Face Risk of Second Cancer: Study | Cancer.comHodgkin Lymphoma Survivors Face Risk of Second Cancer: Study | Cancer.com
MONDAY, March 13, 2017 (HealthDay News) -- The risk of developing a second type of cancer may be high among Hodgkin lymphoma survivors, especially those with a family history of cancer. Thats the finding of a new European study in which researchers examined data from more than 9,500 Hodgkin lymphoma patients. Hodgkin lymphoma, once known as Hodgkins disease, is a cancer that starts in the white blood cells called lymphocytes. Lymphocytes are part of the immune system, according to the American Cancer Society.
NCCN Guidelines for Patients® | Hodgkin LymphomaNCCN Guidelines for Patients® | Hodgkin Lymphoma
54 NCCN Guidelines for Patients ® Hodgkin Lymphoma, Version 1.2015 4 Treatment guide: Classical Hodgkin lymphoma Review Review • First-time treatment for classic Hodgkin lymphoma almost always consists of chemotherapy and radiation therapy. Sometimes, chemotherapy alone is given if it works really well. More chemotherapy is given to cancers that are larger or more widespread. • Refractory cancer is cancer that isnt cured during first-time treatment. Chemotherapy is often first used for treatment. If the cancer responds well, you may have a stem cell transplant with or without radiation therapy. If the cancer responds less well, you may receive other drug treatments with or without radiation therapy. Radiation therapy alone is also an option to treat refractory disease following chemotherapy. • A relapse is cancer that re-appears on tests after a cancer-free period. Treatment options for stage IA or IIA depend on whether you had radiation therapy before. If not, chemotherapy with or ...
Hodgkin Lymphoma Treatment Options - Shenandoah OncologyHodgkin Lymphoma Treatment Options - Shenandoah Oncology
If Hodgkin lymphoma returns after treatment, you may receive stem cell transplantation. A transplant of your own blood-forming stem cells (autologous stem cell transplantation) allows you to receive high doses of chemotherapy, radiation therapy, or both. The high doses destroy both Hodgkin lymphoma cells and healthy blood cells in the bone marrow.. Stem cell transplants take place in the hospital. Before you receive high-dose treatment, your stem cells are removed and may be treated to kill lymphoma cells that may be present. Your stem cells are frozen and stored. After you receive high-dose treatment to kill Hodgkin lymphoma cells, your stored stem cells are thawed and given back to you through a flexible tube placed in a large vein in your neck or chest area. New blood cells develop from the transplanted stem cells.. ...
MRIMS JournalMRIMS Journal
Kandukuri Mahesh Kumar1, V. Indira2, Sudhir Kumar Vujhini3 1Assistant Professor, 2Prof & HOD, 3Associate Professor, Department of Pathology, Malla Reddy Institute of Medical Sciences, Suraram, Hyderabad.. Abstract Of all the pediatric malignancies, lymphomas account for about 10-15% of the cases with half of them diagnosed as Hodgkins lymphoma. Remarkably, this malignancy has a high cure rate with a 5-year survival rate approaching 95%. Hodgkins lymphoma has an overall incidence rate of 14 per 100,000 less than 15 years of age. It has a typical bimodal distribution with respect to age. In developed countries, the peak incidence is seen in young adults and the elderly. While, in developing countries the incidence is higher among children and young adults with a male preponderance. Histologically, mixed cellularity subtype of classical Hodgkins lymphoma occurs commonly in the children and in developing countries. We report three typical cases of classical Hodgkins lymphoma, mixed cellularity ...
Hodgkin Lymphoma Treatment OptionsHodgkin Lymphoma Treatment Options
People with Hodgkin lymphoma may be treated with chemotherapy, radiation therapy, or both.. If Hodgkin lymphoma comes back after the treatment of lymphoma, doctors call this a relapse or recurrence. People with Hodgkin lymphoma that comes back after treatment may receive high doses of chemotherapy, radiation therapy, or both, followed by stem cell transplantation.. Chemotherapy. Chemotherapy for Hodgkin lymphoma uses drugs to kill lymphoma cells. It is called systemic therapy because the drugs travel through the bloodstream. The drugs can reach lymphoma cells in almost all parts of the body.. Usually, more than one drug is given. Most drugs for Hodgkin lymphoma are given through a vein (intravenous), but some are taken by mouth.. Chemotherapy is given in cycles. You have a treatment period followed by a rest period. The length of the rest period and the number of treatment cycles depend on the stage of your disease and on the anticancer drugs used.. You may have your treatment in a clinic, at ...
Prospective coronary heart disease screening in asymptomatic Hodgkin lymphoma patients using coronary computed tomography...Prospective coronary heart disease screening in asymptomatic Hodgkin lymphoma patients using coronary computed tomography...
To prospectively investigate the coronary artery status using coronary CT angiography (CCTA) in patients with Hodgkin lymphoma treated with combined modalities and mediastinal irradiation....
Conditions InDepth: Hodgkin Lymphoma - Health LibraryConditions InDepth: Hodgkin Lymphoma - Health Library
Adult Hodgkin lymphoma treatment (PDQ)-patient version. National Cancer Institute website. Available at: https://www.cancer.gov/types/lymphoma/patient/adult-hodgkin-treatment-pdq. Updated April 12, 2017. Accessed March 30, 2018.. Hodgkin lymphoma. Leukemia & Lymphoma Society website. Available at: http://www.lls.org/lymphoma/hodgkin-lymphoma?src1=20045&src2=. Accessed March 30, 2018.. Hodgkin lymphoma. Merck Manual Professional Version website. Available at: https://www.merckmanuals.com/professional/hematology-and-oncology/lymphomas/hodgkin-lymphoma. Updated October 2012. Accessed March 30, 2018.. Hodgkin lymphoma (HL). EBSCO DynaMed Plus website. Available at:http://www.dynamed.com/topics/dmp~AN~T114957/Hodgkin-lymphoma-HL. Updated November 22, 2017. Accessed March 30, 2018.. What is Hodgkin lymphoma? American Cancer Society website. Available at: https://www.cancer.org/cancer/hodgkin-lymphoma/about/what-is-hodgkin-disease.html. Updated March 28, 2017. Accessed March 30, 2018. ...
A susceptibility locus for classical Hodgkin lymphoma at 8q24 near MYC/PVT1 predicts patient outcome in two independent cohorts...A susceptibility locus for classical Hodgkin lymphoma at 8q24 near MYC/PVT1 predicts patient outcome in two independent cohorts...
TY - JOUR. T1 - A susceptibility locus for classical Hodgkin lymphoma at 8q24 near MYC/PVT1 predicts patient outcome in two independent cohorts. AU - Ghesquières, Hervé. AU - Larrabee, Beth R.. AU - Casasnovas, Olivier. AU - Maurer, Matthew J.. AU - McKay, James D.. AU - Ansell, Stephen M.. AU - Montgomery, Dorothy. AU - Asmann, Yan W.. AU - Farrell, Katrina. AU - Verney, Aurélie. AU - Slager, Susan L.. AU - Allmer, Cristine. AU - Perrot, Aurore. AU - Delarue, Richard. AU - Habermann, Thomas M.. AU - Dupuis, Jehan. AU - Link, Brian K.. AU - Canioni, Danielle. AU - Dogan, Ahmet. AU - Cozen, Wendy. AU - Jarrett, Ruth F.. AU - Cerhan, James R.. AU - Salles, Gilles. PY - 2018/1. Y1 - 2018/1. KW - Hodgkin lymphoma. KW - MYC. KW - PVT1. KW - polymorphism. KW - prognostic. KW - susceptibility. UR - http://www.scopus.com/inward/record.url?scp=85040376800&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=85040376800&partnerID=8YFLogxK. U2 - 10.1111/bjh.14306. DO - ...
Retrospective study evaluating the safety and efficacy of Nivolumab in treatment of relapsed or refractory Hodgkins Lymphoma...Retrospective study evaluating the safety and efficacy of Nivolumab in treatment of relapsed or refractory Hodgkin's Lymphoma...
This study investigated the toxicity and efficacy of nivolumab as a single agent in the treatment of relapsed or refractory Hodgkins lymphoma (HL) after
Hodgkin Lymphoma: Five Things You Need to Know | Dana-Farber Cancer InstituteHodgkin Lymphoma: Five Things You Need to Know | Dana-Farber Cancer Institute
3. What are the symptoms of Hodgkin lymphoma? The most common signs of Hodgkin lymphoma are swollen (painless) lymph nodes in the neck, underarm, or groin, as well as fever, night sweats and weight loss. Other symptoms can include itchy skin, fatigue, cough or shortness of breath.. 4. How do doctors diagnose Hodgkin lymphoma? Typically, the doctor will first conduct a physical exam to check for signs of health and any unusual lumps. The doctor will also check routine blood tests and perform scans, such as a CT scan or MRI.. A biopsy of involved tissue or lymph nodes is essential to make a diagnosis. A pathologist then examines the lymph node tissue to look for the malignant B cells.. A doctor may decide to run additional blood tests, including a blood chemistry study and a check for erythrocyte sedimentation rate.. 5. What are the treatment options for Hodgkin lymphoma? There are two main tools used in standard treatment for Hodgkin lymphoma: Chemotherapy and radiation therapy.. Combination ...
Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous...Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous...
TY - JOUR. T1 - Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy. T2 - KEYNOTE-087 subgroup analysis. AU - Zinzani, Pier Luigi. AU - Chen, Robert. AU - Armand, Philippe. AU - Johnson, Nathalie A.. AU - Brice, Pauline. AU - Radford, John. AU - Ribrag, Vincent. AU - Molin, Daniel. AU - Vassilakopoulos, Theodoros P.. AU - Tomita, Akihiro. AU - von Tresckow, Bastian. AU - Shipp, Margaret A.. AU - Lin, Jianxin. AU - Nahar, Akash. AU - Balakumaran, Arun. AU - Moskowitz, Craig H.. PY - 2020/3/20. Y1 - 2020/3/20. UR - http://www.scopus.com/inward/record.url?scp=85078638645&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=85078638645&partnerID=8YFLogxK. U2 - 10.1080/10428194.2019.1702178. DO - 10.1080/10428194.2019.1702178. M3 - Letter. C2 - 31905294. AN - SCOPUS:85078638645. VL - 61. SP - 950. EP - 954. JO - Leukemia and Lymphoma. JF - Leukemia ...
High frequency of primary refractory disease and low progression-free survival rate of Hodgkins lymphoma: a decade of...High frequency of primary refractory disease and low progression-free survival rate of Hodgkin's lymphoma: a decade of...
Background. Reports dealing with clinical outcomes of classical Hodgkins lymphoma in low- to middle-income countries are scarce and response to therapy is poorly documented. This report describes the characteristics and clinical outcomes of patients with classical Hodgkins lymphoma from a single institution in Latin America.. Method. A retrospective study was conducted over ten years of patients with classical Hodgkins lymphoma treated at a referral center. Progression-free and overall survival rates were estimated by Kaplan-Meier analysis. The univariate Cox regression model was used to estimate associations between important variables and clinical outcomes.. Main results. One hundred and twenty-eight patients were analyzed. The mean age was 28.5 years. The five-year progression-free and overall survival were 37.3% and 78.9%, respectively. Of the whole group, 55 (43%) were primary refractory cases. Only 39/83 (47%) patients with advanced disease vs. 34/45 (75.6%) in early stages ...
Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkins disease: a...Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a...
PURPOSE: To assess the effect of more extensive radiotherapy and of adjuvant combination chemotherapy on long-term outcome of early-stage Hodgkins disease. METHODS: In a collaborative worldwide systematic overview, individual patient data were centrally reviewed on 1,974 patients in eight randomized trials of more versus less extensive radiotherapy and on 1,688 patients in 13 trials of radiotherapy plus chemotherapy versus radiotherapy alone. Crude mortality data on 226 patients in two other trials of chemotherapy were also reviewed. RESULTS: More extensive radiotherapy reduced the risk of treatment failure (resistant or recurrent disease) at 10 years by more than one third (31.3% v 43.4% failures; P | .00001), but there was no apparent improvement in overall 10-year survival (77.1 % v 77.0% alive). The addition of chemotherapy to radiotherapy halved the 10-year risk of failure (15.8% v 32.7%; P | .00001), with a small, nonsignificant improvement in survival (79.4% v 76.5% alive). This involved a
A higher Absolute Monocyte Count (AMC) predicts poor OS and PFS in patients with classical Hodgkin Lymphoma and Nodular...A higher Absolute Monocyte Count (AMC) predicts poor OS and PFS in patients with classical Hodgkin Lymphoma and Nodular...
cHL: Evaluation of 1,450 patients - Higher Absolute Monocyte Count (AMC) is poor predictor of 5-year PFS and 5-year OS in patients with Nodular Sclerosis (NS) classical Hodgkin Lymphoma
The Hodgkins Lymphoma Awareness Shop Blog: December 2007The Hodgkin's Lymphoma Awareness Shop Blog: December 2007
The Hodgkins Lymphoma Violet Ribbon Awareness T-Shirt Shop was established in February 2007 by a pair of sisters, one who survived two battles of Hodgkins Lymphoma and the other who saved her life by donating her stem cells for a life saving syngeneic stem cell transplant to help her sister. Through their partnership with Cafepress, they open their shop to help raise awareness for what is deem a rare and easy cancer known as Hodgkins Lymphoma (aka Hodgkins Disease). Through their cancer awareness t-shirts, apparel and merchandise representing Hodgkins Lymphoma Awareness, they hope to bring attention to this rare and misunderstood cancer. The violet ribbon color was chosen in concurrence with the non-profit organization "curehodgkins" mission and adoption of the Violet Ribbon color in 2001 as the official symbol of unification for Hodgkins Lymphoma, its patients, survivors and their families. They continue the Violet Ribbon Campaigns mission in honor of all those affected by Hodgkins ...
HD7, HD8, HD10, and HD11 - updated analyses based on long-term follow-up of four German Hodgkin Study Group trials in early...HD7, HD8, HD10, and HD11 - updated analyses based on long-term follow-up of four German Hodgkin Study Group trials in early...
Updated analyses based on long-term follow-up of four German Hodgkin Study Group (GHSG) trials (HD7, HD8, HD10, and HD11) in early stage Hodgkin Lymphoma (HL)
Hodgkins lymphoma and emme - Answers on HealthTapHodgkins lymphoma and emme - Answers on HealthTap
Doctor answers on Symptoms, Diagnosis, Treatment, and More: Dr. Fay on hodgkins lymphoma and emme: Primarily, hodgkins lymphoma teens to spread from one lymph node site to an adjacent site. Non hodgkins lymphoma is more likely to skip lymph node chains to spread distantly. This is why local radiation has historically be more important in the treatment of hodgkins than non hodgkins. for topic: Hodgkins Lymphoma And Emme
Hematology: Hodgkin lymphoma (Hodgkin disease) | Stem cell transplant. Treatment in Aachen, Germany | BookingHealthHematology: Hodgkin lymphoma (Hodgkin disease) | Stem cell transplant. Treatment in Aachen, Germany | BookingHealth
Hematology: Hodgkin lymphoma (Hodgkin disease) | Stem cell transplant. Treatment in Aachen, Germany ✈ Find the best medical programs at BookingHealth - ✔Compare the prices ✔Online booking.
Hodgkin lymphoma (Hodgkin disease) | Stem cell transplant. Hematology: Treatment in Germany, Frankfurt am Main hospitals on...Hodgkin lymphoma (Hodgkin disease) | Stem cell transplant. Hematology: Treatment in Germany, Frankfurt am Main hospitals on...
Hodgkin lymphoma (Hodgkin disease) | Stem cell transplant. Hematology: Treatment in Frankfurt am Main, Germany ✈. Prices on BookingHealth.com - booking treatment online!
Plus itPlus it
Patients with otherwise treatment-resistant Hodgkin lymphoma could benefit from chimeric antigen receptor T-cell (CART) therapy. However, Hodgkin lymphoma lacks CD19 and contains a highly immunosuppressive tumor microenvironment (TME). We hypothesized that in Hodgkin lymphoma, CART should target both malignant cells and the TME. We demonstrated CD123 on both Hodgkin lymphoma cells and TME, including tumor-associated macrophages (TAM). In vitro, Hodgkin lymphoma cells convert macrophages toward immunosuppressive TAMs that inhibit T-cell proliferation. In contrast, anti-CD123 CART recognized and killed TAMs, thus overcoming immunosuppression. Finally, we showed in immunodeficient mouse models that CART123 eradicated Hodgkin lymphoma and established long-term immune memory. A novel platform that targets malignant cells and the microenvironment may be needed to successfully treat malignancies with an immunosuppressive milieu.. Significance: Anti-CD123 chimeric antigen receptor T cells target both ...
Anna Sureda MD PhD: An Intelligent Way to Deliver High Doses of a Very Potent Cytotoxic Agent Without Significant Toxicity -...Anna Sureda MD PhD: "An Intelligent Way to Deliver High Doses of a Very Potent Cytotoxic Agent Without Significant Toxicity" -...
Answer: There were several updates of both company-sponsored (e.g. the AETHERA trial) and investigator developed prospective clinical trials that further indicate the efficacy and safety of the use of brentuximab vedotin in patients with relapsed / refractory (r/r) Hodgkin lymphoma. The results of these studies will further improve the outcome of r/r Hodgkin lymphoma patients.. Question: What are the benefits of these engineered and complex novel drugs in the treatment of Hodgkin lymphoma and other cancers?. Answer: They represent a completely different way to treat patients with Hodgkin lymphoma (and other types of hematological malignancies that express the CD30 antigen in the cell surface). It represents a very intelligent way to deliver high doses of a very potent cytotoxic agent without giving the patient significant toxicity.. CD30 is a cell surface antigen expressed on malignant HL Reed-Sternberg cells and targeted by brentuximab vedotin, which comprises a CD30-targeted monoclonal ...
Early-Stage Hodgkin Lymphoma: A Case-Based Review of the Recent LiteratureEarly-Stage Hodgkin Lymphoma: A Case-Based Review of the Recent Literature
The treatment of early-stage Hodgkin lymphoma remains controversial with combined modality therapy and chemotherapy alone representing acceptable options. Observation studies show a progressive decline in the use of radiation secondary to late complications but also suggest a decrease in survival for non-irradiated patients. Early PET CT scans have been incorporated into strategies of response-adapted therapy but have been imperfect in identifying patients who may require more aggressive treatment. In the absence of radiation, further improvement in the cure rate is likely to require better chemotherapy such as the incorporation of two cycles of dose-escalated BEACOPP or possibly the substitution of brentuximab for bleomycin. The treatment of patients who have relapse after abbreviated chemotherapy alone is not standardized and it remains unclear whether these patients should all receive highdose chemotherapy and autologous stem cell rescue or whether a significant fraction can be salvaged with
Final appraisal determination | Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma | Guidance | NICEFinal appraisal determination | Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma | Guidance | NICE
Evidence-based recommendations on pembrolizumab (Keytruda) for treating relapsed or refractory classical Hodgkin lymphoma (cHL) in adults
T-cell/histiocyte-rich large B-cell lymphoma - transformation of Nodular lymphocyte predominant Hodgkin lymphoma in the bone...T-cell/histiocyte-rich large B-cell lymphoma - transformation of Nodular lymphocyte predominant Hodgkin lymphoma in the bone...
We use cookies to ensure that we give you the best experience on our website. If you click Continue well assume that you are happy to receive all cookies and you wont see this message again. Click Find out more for information on how to change your cookie settings ...
American Registry of Pathology Expert Opinions: Immunohistochemical evaluation of classic Hodgkin lymphoma<...American Registry of Pathology Expert Opinions: Immunohistochemical evaluation of classic Hodgkin lymphoma<...
TY - JOUR. T1 - American Registry of Pathology Expert Opinions. T2 - Immunohistochemical evaluation of classic Hodgkin lymphoma. AU - OMalley, Dennis P.. AU - Dogan, Ahmet. AU - Fedoriw, Yuri. AU - Medeiros, L. Jeffrey. AU - Ok, Chi Young. AU - Salama, Mohamed. PY - 2019/4/1. Y1 - 2019/4/1. N2 - The diagnosis of classic Hodgkin lymphoma requires immunohistochemical confirmation in most cases and one can argue for these studies as standard-of-care in the diagnostic workup. The authors propose a panel of studies for primary identification of CHL to include: CD3, CD20, CD15, CD30 and PAX5. When pattern discordances are identified, additional assessment is recommended. In the case of overexpression of B lineage markers by Hodgkin/Reed-Sternberg cells, or a differential diagnosis that includes large B-cell lymphoma or variants, additional markers recommended are: CD45, OCT2, BOB1, CD79a and MUM1/IRF4. If primary mediastinal large B cell lymphoma is considered in the differential diagnosis, suggested ...
Lirias: Macrophages in T cell/histiocyte rich large B cell lymphoma strongly express metal-binding proteins and show a bi...Lirias: Macrophages in T cell/histiocyte rich large B cell lymphoma strongly express metal-binding proteins and show a bi...
Abundant macrophage infiltration in tumors often correlates with a poor prognosis. T cell/histiocyte rich large B cell lymphoma (THRLBCL) is a distinct aggressive B cell lymphoma entity showing a high macrophage content. To further elucidate the role of tumor-associated macrophages in THRLBCL, we performed gene expression profiling of microdissected histiocyte subsets of THRLBCL, nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), Piringer lymphadenitis, sarcoidosis, nonspecific lymphadenitis and monocytes from peripheral blood. In a supervised principal component analysis, histiocytes from THRLBCL were most closely related to epithelioid cells from NLPHL, with both types of cells expressing genes related to proinflammatory and regulatory macrophage activity. Moreover, histiocytes from THRLBCL strongly expressed metal-binding proteins like MT2A, by which histiocytes of THRLBCL can be distinguished from the other histiocyte subsets investigated. Interestingly, the validation at the protein ...
Epstein-Barr virus and childhood Hodgkins disease in Honduras and the United States. - Semantic ScholarEpstein-Barr virus and childhood Hodgkin's disease in Honduras and the United States. - Semantic Scholar
In industrialized populations, Hodgkins disease (HD) has an initial peak in young adulthood, whereas in economically developing populations the initial peak occurs in childhood. This pattern resembles that of infection with poliovirus and suggests an infectious cofactor in the etiology. Serologic studies have linked Epstein-Barr virus (EBV) to young adult and adult HD, and viral nucleic acids and antigens have been detected in a subset of Hodgkins tumor specimens. To investigate the association of childhood HD with EBV we studied tumor specimens from 11 children treated in Honduras and 25 children treated in the United States using in situ hybridization and antigen detection techniques. Among the patients from Honduras, tumor specimens from all cases were EBV positive. Among the patients from the United States, tumor specimens from six of seven patients with mixed cellularity histology, 2 of 15 with nodular sclerosis histology, and neither of two patients with lymphocyte-predominant histologies were
Rare Occurrence of Classical Hodgkins Disease as a T Cell Lymphoma | JEMRare Occurrence of Classical Hodgkin's Disease as a T Cell Lymphoma | JEM
Derivation of H/RS cells from mature B cells was previously demonstrated in 18 out of 18 informative unselected cases of cHD analyzed in Cologne and Frankfurt (3)(4)(5)(17)(18)(19). In addition, recent results obtained by others indicate B cell derivation of H/RS cells in 24 out of 25 cases of cHD (20). On the other hand, in a nonselected collection of 13 cases of primary cHD, Daus and colleagues did not detect clonal TCR-γ gene rearrangements in micromanipulated H/RS cells from any of these cases (21). Therefore, these data collectively indicate that cHD represents a homogenous entity as a B cell lymphoma.. However, there are some observations raising the possibility that-in a subset of cHD-the tumor cells might stem from T lymphocytes. Some putative H/RS cell lines, for example, are derived from T cells (2). For these cell lines, proof of derivation from H/RS cells in the patients is missing. Furthermore, a TCR-α gene rearrangement was amplified from whole tissue DNA of lymphomatoid ...
Pheochromocytoma | DocsfordPheochromocytoma | Docsford
Leukemia & Lymphoma (Contd.) Disease Cause/Risk Factors Symptoms Buzzwords Other Cervical, Supraclavicular or mediastinal nodes Lacunar Reed Sternberg Cells Hodgkins Disease Most common type; affects adolescent or young adult women EBV Variable cell composition & necrosis Collagen Bands (Nodular Sclerosis) Staging (usually I or II) determines treatment; Good prognosis CD15 & CD30 Women Variable cell composition & focal necrosis Hodgkins Disease Disordered fibrosis 2ndEBV Classic Reed Sternberg Cells most common type; men more common (Mixed Cellularity) Eosinophils, Plasma & T Cells Staging determines treatment; Guarded prognosis CD15 & CD30 1) Diffuse Fibrosis - RS Cells embedded in Fairly common - usually in older patients Poor Prognosis Hodgkins Disease fibrous stroma Often Bone Marrow Involvement (Stage III or IV) EBV Many Reed Sternberg Cells (Lymphocyte Depletion) 2) Reticular - RS Cells in sheets Poor prognosis Bone Marrow ? #s of Reed Sternberg Cells Usually not a true Hodgkins ...
A Pilot Phase II Study With BRENTUXIMAB VEDOTIN as Pre-ASCT Induction Therapy in Relapsed/Refractory Hodgkins Lymphoma...A Pilot Phase II Study With BRENTUXIMAB VEDOTIN as Pre-ASCT Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma...
A pilot phase II study with brentuximab vedotin as pre-autologous stem cell transplantation induction therapy in relapsed or refractory Hodgkins lymphoma
Health Canada Approves ADCETRIS® (Brentuximab Vedotin) for the Treatment of Relapsed or Refractory Hodgkin Lymphoma (HL) and...Health Canada Approves ADCETRIS® (Brentuximab Vedotin) for the Treatment of Relapsed or Refractory Hodgkin Lymphoma (HL) and...
Health Canada Approves ADCETRIS® (Brentuximab Vedotin) for the Treatment of Relapsed or Refractory Hodgkin Lymphoma (HL) and Systemic Anaplastic Large Cell Lymphoma (sALCL)
ICD-10-CM Code C81.18 - Nodular sclerosis classical Hodgkin lymphoma, lymph nodes of multiple sitesICD-10-CM Code C81.18 - Nodular sclerosis classical Hodgkin lymphoma, lymph nodes of multiple sites
Nodular sclerosis (or NSHL) is a form of Hodgkins lymphoma that is the most common subtype of HL in developed countries. It affects females slightly more than males and has a median age of onset at ~28 years. It is composed of large tumor nodules with lacunar Reed-Sternberg cell (RS cells) surrounded by fibrotic collagen bands. ...
Targeting cellular FLICE-like inhibitory protein as a novel approach to the treatment of Hodgkins lymphoma.Targeting cellular FLICE-like inhibitory protein as a novel approach to the treatment of Hodgkin's lymphoma.
Hodgkins lymphoma is one of the most common lymphoid cancers, particularly among young adults. Although there have been dramatic improvements in the treatment of Hodgkins lymphoma, leading to high cure rates in some groups, current combination chemotherapy regimes are associated with significant secondary complications in long-term survivors. Furthermore, although a proportion of patients with Hodgkins lymphoma will be cured, there still remains a significant rate of relapse and also a smaller proportion of poor responders who will go on to die of their disease. Therefore, developments in the treatment of Hodgkins lymphoma must be directed at improving cure rates and reducing the burden of secondary complications. In recent years, the underlying pathogenesis of Hodgkins lymphoma has become better understood. In particular, it is emerging that a key pathogenic event in Hodgkins lymphoma is protection from Fas-induced cell death. Recent studies by the authors group, and others, have ...
Thymic epithelial hyperplasia with nodular sclerosis Hogkins disease<...Thymic epithelial hyperplasia with nodular sclerosis Hogkin's disease<...
TY - JOUR. T1 - Thymic epithelial hyperplasia with nodular sclerosis Hogkins disease. AU - Ito, Wataru. AU - Kojima, Kensuke. AU - Fujiwara, Kumi. AU - Nanba, Yasuo. AU - Yoshino, Tadashi. AU - Shinagawa, Katsuji. AU - Ishimaru, Fumihiko. AU - Ikeda, Kazuma. AU - Niiya, Kenji. AU - Tanimoto, Mitsune. PY - 2002/11/1. Y1 - 2002/11/1. N2 - We report a case of simultaneous occurrence of thymic epithelial hyperplasia and Hodgkins disease. A computed tomographic scan of the chest revealed a tumor in the anterior mediastinum and conspicuous swelling of lymph nodes in the upper and lower mediastinum. The anterior mediastinal tumor was histologically diagnosed as thymic epithelial hyperplasia, while the lymph nodes were nodular sclerosis Hodgkins disease. Our findings suggest that thymic hyperplasia might be directly involved in the pathology of at least some cases of Hodgkins disease.. AB - We report a case of simultaneous occurrence of thymic epithelial hyperplasia and Hodgkins disease. A computed ...
Hodgkin Disease | Lymphoma | Hodgkin Lymphoma | MedlinePlusHodgkin Disease | Lymphoma | Hodgkin Lymphoma | MedlinePlus
Hodgkin disease is a type of lymphoma, cancer of the lymph system. It is a rare; but serious condition. Can cause swelling in neck, armpits or groin.
In remission from IIB nodular, sclerosing Hodgkins, have recurring lump on groin, diagnosed as lipoma. Diagnosis correct? -...In remission from IIB nodular, sclerosing Hodgkin's, have recurring lump on groin, diagnosed as lipoma. Diagnosis correct? -...
Question - In remission from IIB nodular, sclerosing Hodgkins, have recurring lump on groin, diagnosed as lipoma. Diagnosis correct?. Ask a Doctor about diagnosis, treatment and medication for Lipoma, Ask a Dermatologist
Hodgkin lymphoma - WikipediaHodgkin lymphoma - Wikipedia
Hodgkin lymphoma was first described in an 1832 report by Thomas Hodgkin, although Hodgkin noted that perhaps the earliest reference to the condition was provided by Marcello Malpighi in 1666.[51][13] While occupied as museum curator at Guys Hospital, London, Hodgkin studied seven with painless lymph node enlargement. Of the seven cases, two were under the care of Richard Bright, one was of Thomas Addison, and one was of Robert Carswell.[51] Carswells report of this seventh person was accompanied by numerous illustrations that aided early descriptions of the disease.[52]. Hodgkins report on these seven people, entitled "On some morbid appearances of the absorbent glands and spleen", was presented to the Medical and Chirurgical Society of London in January 1832 and was subsequently published in the societys journal, Medical-Chirurgical Society Transactions.[51] Hodgkins paper went largely unnoticed, however, even despite Bright highlighting it in an 1838 publication.[51] Indeed, Hodgkin ...
Study Estimates Risk of Premature Menopause After Treatment for Hodgkin Lymphoma - The ASCO PostStudy Estimates Risk of Premature Menopause After Treatment for Hodgkin Lymphoma - The ASCO Post
Previous research has suggested that women with Hodgkin lymphoma who receive certain types of chemotherapy or radiotherapy are at increased risk of future infertility, but there was insufficient information to provide patients with detailed advice. In a study published in the Journal of the National Cancer Institute, Swerdlow et al estimated the risk of premature menopause in women being treated for Hodgkin lymphoma.1 The findings are based on the experience of more than 2,000 young women in England and Wales over a period of more than 40 years.. The new study, led by scientists at The Institute of Cancer Research, London, provides precise estimates of risk for women depending on which treatment types and doses they received and at what age, allowing doctors to give them detailed advice about their risks of future infertility.. Study Details. The research team followed 2,127 women who had been treated for Hodgkin lymphoma in England and Wales at ages younger than 36 years from 1960 to 2004. All ...
Primary intracerebra Hodgkins disease mimicking meningioma: Case report<...Primary intracerebra Hodgkin's disease mimicking meningioma: Case report<...
TY - JOUR. T1 - Primary intracerebra Hodgkins disease mimicking meningioma. T2 - Case report. AU - Johnson, Mahlon D.. AU - Kinney, Marsha C. AU - Scheithauer, Bernd W.. AU - Briley, Randall J.. AU - Hamilton, Kathy. AU - McPherson, Warren F.. AU - Barton, John H.. PY - 2000. Y1 - 2000. N2 - OBJECTIVE AND IMPORTANCE: A rare case of dura-based primary cerebral Hodgkins disease clinically and radiographically indistinguishable from a meningioma is described. CLINICAL PRESENTATION: A 55-year-old immunocompetent woman presented with headaches and ataxia. Magnetic resonance images demonstrated a circumscribed diffusely enhancing mass with a dural tail attached to the cerebellar tentorium. INTERVENTION: Operation inspection also suggested a meningioma, but a frozen section of the firm mass revealed an inflammatory lesion. Subsequent pathological analysis demonstrated Hodgkins disease, nodular sclerosing type. An extensive workup revealed no systemic disease. CONCLUSION: This case illustrates the ...
Update on Salvage Options in Relapsed/Refractory Hodgkin Lymphoma after AutotransplantUpdate on Salvage Options in Relapsed/Refractory Hodgkin Lymphoma after Autotransplant
Despite a high clinical success, relapse in Hodgkin lymphoma occurs in 10–30% of cases and 5–10% patients are nonresponsive to initial chemotherapy. The standard management of these patients includes high-dose chemotherapy followed by autologous stem cell transplant. However, 50% of patients ultimately relapse after autotransplant which poses a big challenge. Allogeneic stem cell transplantation offers the only chance of cure in these patients. For patients who are not candidates for allogeneic stem cell transplantation, achieving cure with other possible options is highly unlikely, and thus the treatment plan becomes noncurative. Various novel agents have shown promising results but the duration of response is short lived. A standard approach to deliver the most effective treatment for these patients is still lacking. This review focuses on the treatment options currently available for relapsed and refractory disease after autotransplant.
Persistent Immunologic Abnormalities in Long-Term Survivors of Advanced Hodgkins Disease | Annals of Internal Medicine |...Persistent Immunologic Abnormalities in Long-Term Survivors of Advanced Hodgkin's Disease | Annals of Internal Medicine |...
Immunologic studies were done on 47 long-term survivors of Hodgkins disease who had been treated with MOPP chemotherapy (mechlorethamine, vincristine, procarbazine, and prednisone). Percentages of E rosettes and mitogen-induced lymphocyte proliferation were significantly reduced compared to those in normal control subjects. There was no tendency for these abnormalities to return to the normal range with increasing disease-free intervals. No abnormalities of B-cell number or function were detected. Long-term survivors of advanced diffuse histiocytic lymphoma treated with comparable chemotherapy, who served as a control population, had significantly higher percentages of E rosettes and no reduction in mitogen-induced lymphocyte proliferation. Thus these persistent immunologic abnormalities cannot be attributed to chemotherapy alone. The presence of similar immunologic abnormalities in untreated patients with Hodgkins disease of all stages and in patients cured by either MOPP or radiotherapy ...
Adriamycin, bleomycin, vinblastine and imidazole carboxamide (ABVD) therapy for advanced Hodgkins disease resistant to mustine...Adriamycin, bleomycin, vinblastine and imidazole carboxamide (ABVD) therapy for advanced Hodgkin's disease resistant to mustine...
Forty-one previously treated patients with advanced Hodgkins disease were treated with a combination chemotherapy regimen - ABVD (adriamycin, bl
International Prognostic Score for Asymptomatic Early-stage Chronic Lymphocytic Leukemia. | OnMedicaInternational Prognostic Score for Asymptomatic Early-stage Chronic Lymphocytic Leukemia. | OnMedica
Most patients with chronic lymphocytic leukemia (CLL) are diagnosed with early stage disease and managed with active surveillance. The individual course of subjects with early stage CLL is heterogeneous and their probability of needing treatment is hardly anticipated at diagnosis. We aimed at developing an international prognostic score to predict time to first treatment (TTFT) in CLL patients with early, asymptomatic disease (IPS-E). Individual patient data from 11 international cohorts of patients with early stage CLL (n=4933) were analyzed to build and validate the prognostic score. Three covariates were consistently and independently correlated with TTFT: unmutated IGHV genes, absolute lymphocyte count ,15 x109/l, and presence of palpable lymph nodes. The IPS-E was the sum of the covariates (one point each), and separated low-risk (score 0), intermediate-risk (score 1) and high-risk patients (score 2-3) showing a distinct TTFT. The score accuracy was validated in 9 cohorts staged by the ...
Seattle Genetics Adcetris earns FDA priority review status - PMLiVESeattle Genetics' Adcetris earns FDA priority review status - PMLiVE
Seattle Genetics Adcetris has received a boost after the US Food and Drug Administrations (FDA) granted the lymphoma drug priority review status.. Adcetris (brentuximab vedotin), an antibody-drug conjugate, was awarded the status based on the results of the phase III ECHELON-1 trial, which had a primary endpoint of an improved PFS in previously untreated advanced classical Hodgkin lymphoma patients.. Data from the trial - which evaluated a combination of Adcetris plus Adriamycin, vinblastine, dacarbazine (ADC) - showed a 23% reduction in the risk of progression, death or need for additional therapy, achieving its primary endpoint.. Clay Siegall, president and chief executive officer of Seattle Genetics, said: "We recently reported the primary data from the phase III ECHELON-1 clinical trial in the Plenary Scientific Session of the 2017 ASH annual meeting.. "Data from the trial demonstrated superior activity of the Adcetris-containing regimen over standard of care, and we are working with the ...
Treatment Results of Hodgkins Disease from 1977 to 1991 in National Taiwan University Hospital<...Treatment Results of Hodgkin's Disease from 1977 to 1991 in National Taiwan University Hospital<...
TY - JOUR. T1 - Treatment Results of Hodgkins Disease from 1977 to 1991 in National Taiwan University Hospital. AU - 雷, 德. AU - 許, 智捷. AU - 鍾, 娜娜. AU - 王, 博民. AU - 黃, 昭源. AU - 丁, 禮莉(Lai-Lei Ting). PY - 1997. Y1 - 1997. N2 - Purpose: To evaluate the response and outcome of patients of Hodgkins disease undergoing different treatment modalities. Materials and Methods: We reviewed clinical records of Hodgkins disease who received chemotherapy (C/T), radiotherapy (R/T) or combined chemotherapy and radiotherapy (CRT) from 1977 to 1991 in National Taiwan University Hospital ( NTUH). The 5-year survival rate (SR) and 5-year freedom from relapse rate (FFR) in different stages were calculated and classified by different treatment modalities. Result: The overall 5-year survival rate (SR) and 5-year freedom from relapse rate (FFR) were summarized for stage I+Ⅱ, Ⅲ and IV diseases. In stage I+Ⅱ diseases, the SR of CIT, RIT and CRT groups were 50%, 60% and 89%; the ...
CHAPTER 102 HODGKIN LYMPHOMA | Free Medical TextbookCHAPTER 102 HODGKIN LYMPHOMA | Free Medical Textbook
CHAPTER 102 HODGKIN LYMPHOMA Williams Hematology CHAPTER 102 HODGKIN LYMPHOMA SANDRA J. HORNING Definition and History Etiology and Pathogenesis Origin of the Reed-Sternberg Cell Oncogenes Cytogenetic Studies Association with EBV Association with the Non-Hodgkin Lymphomas Cytokines Immunologic Dysfunction Epidemiology Clinical Features Presenting Manifestations Laboratory Features Differential Diagnosis Therapy, Course, and Prognosis Treatment Modalities Disease Stage…
Plus itPlus it
Purpose: There is evidence that Hodgkin Reed-Sternberg (HRS) cells in classical Hodgkin lymphoma (cHL) could display some molecular and morphologic markers of cellular senescence (CS). We hypothesized that CS mechanisms may have potential prognostic relevance in cHL and investigated whether the expression of the well-established CS biomarkers p21CIP1/WAF1 and p16INK4a by HRS cells might be predictive of the probability of event-free survival (EFS).. Experimental Design: The study analyzed a retrospective cohort of 147 patients and the results were validated on a cohort of 91 patients independently diagnosed and treated in a different institution. p16INK4a and p21CIP1/WAF1 were categorized as dichotomous variables (, or ≥ 30% of HRS cells at diagnosis) and evaluated in univariate and multivariate analysis.. Results: Both molecules were independent prognostic factors. A positive staining of one of the two molecules in more than 30% HRS cells predicted a better EFS (P , 0.01). ...
Another preventable death thanks to alternative medicine [Respectful Insolence] | Science and TechnologyAnother preventable death thanks to alternative medicine [Respectful Insolence] | Science and Technology
Hodgkins lymphoma. Why is it always Hodgkins lymphoma? OK, its not always Hodgkins lymphoma, but it frequently is. Whats so frustrating about seeing young people with Hodgkins lymphoma choosing quackery instead of effective medicine is that Hodgkins lymphoma is so treatable for cure. Indeed, even stage IV Hodgkins lymphoma can be cured about 65% of the time. Sofronsky must have had stage III Hodgkins because the story says she had an estimated 80% chance of beating it with standard treatment. Remember, Hodgkins disease is usually treated with a combination of chemotherapy and radiation therapy.. Of course, the problem is the chemotherapy. Of all the treatments for cancer, chemotherapy tends to be what scares people the most. Its understandable. Take breast cancer, for instance, which I treat surgically. Most women operated on for breast cancer undergo fairly small operations, but even for those who undergo mastectomy, the recovery is generally within a month and the pain not long ...
CD30 / TNFRSF8 (Hodgkin & Reed-Sternberg Cell Marker) Antibody - Without BSA and AzideCD30 / TNFRSF8 (Hodgkin & Reed-Sternberg Cell Marker) Antibody - Without BSA and Azide
... , Mouse Monoclonal Antibody [Clone Ki-1/779 ] validated in IHC, IF, FC (AH12693-100), Abgent
Hodgkins lymphoma - Willamette Valley Cancer InstituteHodgkin's lymphoma - Willamette Valley Cancer Institute
Lymphoma refers to a family of cancers of the lymphatic system, which includes the parts of the immune system responsible for fighting disease and infection. Lymphomas are divided into two categories, Hodgkins and non-Hodgkins.. Hodgkins lymphoma, also known as HL, is a cancer that begins in lymphocytes, the white blood cells responsible for immune system responses. HL begins when a lymphocyte (usually a B cell) becomes abnormal, with the presence of a particular abnormal cell called a Reed-Sternberg cell. (See photo below.). The Reed-Sternberg cell divides to make copies of itself. The new cells divide again and again, making more and more abnormal cells. The abnormal cells dont die when they should, and they dont protect the body from infections or other diseases. Instead, the buildup of extra cells often forms a mass of tissue called a growth or tumor.. HL can start almost anywhere in the body because of the extensive reach of the lymphatic system. Usually, HL is first found in a lymph ...
Hodgkin Lymphoma: DiagnosisHodgkin Lymphoma: Diagnosis
Fine needle aspiration (FNA) or core needle biopsy. Your doctor may choose this type of biopsy if you have swollen lymph nodes in your neck or armpit. For FNA, the doctor uses a very thin, hollow needle. For a core needle biopsy, the doctor uses a slightly bigger needle. The needle is used to take a small sample of tissue from the lymph node. For tumors deeper in the body, ultrasound or CT scans may be used to help the doctor guide the needle into place. A needle biopsy may not remove enough tissue for the pathologist to see cancerous cells. Or the sample may also be too small to tell the type of lymphoma. Because of this, most doctors dont use a needle biopsy to try to diagnose Hodgkin lymphoma. But there are times when a needle biopsy may be helpful. If you have been diagnosed with Hodgkin lymphoma, your doctor may use this to see if swelling in another part of your body is also lymphoma.. ...
Hodgkin lymphoma statistics - Canadian Cancer SocietyHodgkin lymphoma statistics - Canadian Cancer Society
Hodgkin lymphoma is a cancer that causes few deaths in Canada because of effective treatments. Learn about Hodgkin lymphoma statistics in Canadian adults.
Lenalidomide plus metronomic cyclophosphamide for heavely pretreated classical Hodgkin Lymphoma. A phase II trial | OncologyPROLenalidomide plus metronomic cyclophosphamide for heavely pretreated classical Hodgkin Lymphoma. A phase II trial | OncologyPRO
Between 11/2010 and 12/2011, 16 pts were included. The trial was closed early because we observed only 5 responses after 4 cycles. Median age was 34 years (18-77). The median number of previous lines was 5 (2-6). Ten pts were primary refractory and 11 were refractory at inclusion. Twelve pts were R/R a median of 5 months after ASCT and 4 pts never had achieved a chemosensitive status. Five pts had also received aloSCT. Twelve pts presented with extranodal disease at inclusion. A total of 110 cycles were administered, with serious (grade ≥ 3) toxicity in 43 cycles (39%). The most frequent serious toxicities were neutropenia (14% of cycles) and thrombocytopenia (7% of cycles). A toxic death was observed after a septic shock in a non neutropenic pt. An ORR of 38% (1 CR and 5 PR) was observed and 10 pts (62%) achieved clinical benefit (response or disease stabilization for more than 6 months). Median progression free survival (PFS) and overall survival (OS) were 7 and 19 months. With a median ...
Radiation-induced coronary artery disease in Hodgkins disease<...Radiation-induced coronary artery disease in Hodgkin's disease<...
TY - JOUR. T1 - Radiation-induced coronary artery disease in Hodgkins disease. AU - Miltényi, Zsófia. AU - Keresztes, Katalin. AU - Garai, Ildikó. AU - Édes, István. AU - Galajda, Zoltán. AU - Tóth, László. AU - Illés, Árpád. PY - 2004/1/1. Y1 - 2004/1/1. N2 - Purpose Secondary malignant tumours and cardiovascular complications are of great importance among the late complications after treatment for Hodgkins disease (HD) because they may significantly reduce the patients life expectancy. We report on coronary artery disease (CAD) after treatment for HD. Methods and Materials We present the case of two female patients with HD who received mediastinal irradiation after which complete remission was achieved. In 12 and 19 years after the onset of the disease, control examinations revealed ischaemic heart disease, which was confirmed by coronary arteriography and solved by stent implantation in one of the patients and bypass surgery in the other one. Conclusions Ischaemic heart disease ...
Risk of valvular heart disease after treatment for Hodgkin lymphoma. - Nuffield Department of Population HealthRisk of valvular heart disease after treatment for Hodgkin lymphoma. - Nuffield Department of Population Health
BACKGROUND: Hodgkin lymphoma (HL) survivors are at increased risk of developing valvular heart disease (VHD). We evaluated the determinants of the risk and the radiation dose-response. METHODS: A case-control study was nested in a cohort of 1852 five-year HL survivors diagnosed at ages 15 to 41 years and treated between 1965 and 1995. Case patients had VHD of at least moderate severity as their first cardiovascular diagnosis following HL treatment. Control patients were matched to case patients for age, gender, and HL diagnosis date. Treatment and follow-up data were abstracted from medical records. Radiation doses to heart valves were estimated by reconstruction of individual treatments on representative computed tomography datasets. All statistical tests were two-sided. RESULTS: Eighty-nine case patients with VHD were identified (66 severe or life-threatening) and 200 control patients. Aortic (n = 63) and mitral valves (n = 42) were most frequently affected. Risks increased more than linearly with
EXBIO Antibodies Product Data SheetEXBIO Antibodies Product Data Sheet
CD30 is a type I transmembrane glycoprotein of the TNF receptor superfamily. CD30 was originally identified as a cell surface antigen of Hodgkins and Reed-Sternberg cells using monoclonal antibody Ki-1. The ligand for CD30 is CD30L (CD153). The binding of CD30 to CD30L mediates pleiotropic effects including cell proliferation, activation, differentiation, and apoptotic cell death. CD30 has a critical role in the pathophysiology of Hodgkins disease and other CD30+ lymphomas. CD30 acts as a costimulatory molecule in thymic negative selection. In addition to its expression on Hodgkins and Reed-Sternberg cells, CD30 is also found in some non-Hodgkins lymphomas (including Burkitts lymphomas), virus-infected T and B cells, and on normal T and B cells after activation. In T cells, CD30 expression is present on a subset of T cells that produce Th2-type cytokines and on CD4+/CD8+ thymocytes that co-express CD45RO and the IL4 receptor. Soluble form of CD30 (sCD30) serves as a marker reflecting Th2 ...
Laboratory diagnostic testing for classical Hodgkin lymphoma | MDedge Hematology and OncologyLaboratory diagnostic testing for classical Hodgkin lymphoma | MDedge Hematology and Oncology
Copyright © 2020 Frontline Medical Communications Inc., Parsippany, NJ, USA. All rights reserved. Unauthorized use prohibited. The information provided is for educational purposes only. Use of this Web site is subject to the medical disclaimer.. ...
Neoplastic Disorders | Weinbergs Color Atlas of Pediatric Dermatology, 5e | AccessPediatrics | McGraw-Hill MedicalNeoplastic Disorders | Weinberg's Color Atlas of Pediatric Dermatology, 5e | AccessPediatrics | McGraw-Hill Medical
Hodgkin disease Like other lymphoproliferative disorders, Hodgkin disease may have both specific and nonspecific cutaneous manifestations. Figure 24-3 illustrates a relatively rare event in children with Hodgkin disease: the direct infiltration of malignant cells into the skin. A biopsy analysis of these brownish papules, nodules, and plaques reveals a histology similar to that of affected lymph nodes. These lesions may occasionally ulcerate, and pruritus is a distressing symptom. ...
Treatment for Hodgkin lymphomaTreatment for Hodgkin lymphoma
Thanks everyone. We have received 615000 Naria so far. God will surely bless you all for your kindness. Please continue to donate to reach our target to help this young man, no amount is too small. God will never leave you too. Amen. Treatment for Hodgkin lymphoma. DONATE Today! http://bit.ly/Treatment_Hodgkin_lymphoma. Please help to save this young man.. He started having pains in his hand and a small boil at the side of his neck. we thought it was pimple and will go away.. Soon he begin to have pains, we took him to the hosptal in Lagos Nigeria where he was diagnosed with Neurofibroma type 1.. In 2011 with so much pains he was taken to the hospital where he was diagnosed with Neurofibroma type 2 and a surgical excision was attemted in 14 of july 2011 and failed.. After that a CT scan of the neck shows anterior neck mass that is prominently on the left. The mass is bulky, lobulated and has septal enhancement. The mass extend superiorly to the angle of the mandible with intra-thoracic ...
Hodgkin Lymphoma Treatment Options - YouTubeHodgkin Lymphoma Treatment Options - YouTube
Visit the Lymphoma Research Foundations dedicated website for people with Hodgkin lymphoma, www.FocusOnHL.org, for additional information on Hodgkin lymphom...
Persisting fatigue in Hodgkin lymphoma survivors: a systematic review | SpringerLinkPersisting fatigue in Hodgkin lymphoma survivors: a systematic review | SpringerLink
Hodgkin Lymphoma (HL) survivors are at risk for adverse psychosocial events as a result from cancer diagnosis and treatment. Fatigue is one of the most frequently reported long-term symptoms and is of
RECRUIT-TandAb AFM13 - overcoming limitations of monoclonal antibodies in Hodgkin lymphoma | OncologyPRORECRUIT-TandAb AFM13 - overcoming limitations of monoclonal antibodies in Hodgkin lymphoma | OncologyPRO
AFM13 is a RECRUIT-TandAb (CD30xCD16A) for treating Hodgkin Lymphoma by recruiting NK-cells and macrophages to the specific CD30 surface antigen on Reed-Sternberg cells. This redirected immune response leads to potent tumor cell killing. RECRUIT TandAbs are tetravalent and bispecific, and address key deficiencies of monoclonal antibodies such as (i) differential binding to V/F allotypes of CD16A receptor and (ii) non-selective binding to activating CD16A and non-signalling CD16B receptors. Furthermore, RECRUIT-TandAbs have significant advantages over other antibody fragment technologies such as (i) bivalent binding to the targets and, (ii) longer half-life.. AFM13 binds with high affinity to both CD30 and CD16A and is able to rapidly induce lysis of CD30+ cells at picomolar concentrations in the presence of PBMCs. Intensive in vitro characterization demonstrated that AFM13 is specific for the CD16A receptor, which becomes activated only in the presence of tumor cells: there is no systemic ...
The Hodgkins Lymphoma Awareness Shop Blog: From Our Sister Blog: Raising Hodgkins Lymphoma Awareness Because It MattersThe Hodgkin's Lymphoma Awareness Shop Blog: From Our Sister Blog: Raising Hodgkin's Lymphoma Awareness Because It Matters
Unfortunately, it was not the "good cancer" and the road to remission was a bumpy one to say the least. It took a rare syngeneic stem cell transplant and almost two years of back-to-back high dose chemotherapy treatment and radiation therapy to bring our sister into remission status. As a family, we experienced this two-year challenging journey right along our sister. This sobering experience inspired us to do something tangible in our sisters honor and in honor of other cancer warriors and survivors to help promote worldwide awareness for Hodgkins Lymphoma, a cancer wrongly deemed the "good cancer ...
2018 ICD-10-CM Diagnosis Code C81.2: Mixed cellularity Hodgkin lymphoma2018 ICD-10-CM Diagnosis Code C81.2: Mixed cellularity Hodgkin lymphoma
Free, official coding info for 2018 ICD-10-CM C81.2 - includes detailed rules, notes, synonyms, ICD-9-CM conversion, index and annotation crosswalks, DRG grouping and more.
Hodgkins Lymphoma : Symptoms and Treatment in Delhi, NCR India | Max HospitalHodgkin's Lymphoma : Symptoms and Treatment in Delhi, NCR India | Max Hospital
Know more about hodgkins lymphoma causes, symptoms and treatment. Max Hospital is one of the top hodgkins lymphoma treatment hospitals in Delhi NCR, India. Book an appointment online.
Doctors For Non Hodgkins Lymphoma In Pakistan | MARHAMDoctors For Non Hodgkins Lymphoma In Pakistan | MARHAM
Are You In Search Of Online Doctor For Non Hodgkins Lymphoma In Pakistan? Now You Can Easily Find And Consult A Doctor For Non Hodgkins Lymphoma
CD30 antibodies, human - Primary antibodies - Antibodies - MACS Flow Cytometry - Products - Miltenyi Biotec - USACD30 antibodies, human - Primary antibodies - Antibodies - MACS Flow Cytometry - Products - Miltenyi Biotec - USA
Clone REA1085 recognizes the human CD30 antigen, a cell membrane protein, which is a member of the tumor necrosis factor receptor (TNFR) superfamily, and also known as Ki-1. CD30 is used as a tumor marker and is found on Hodgkin/Reed-Sternberg (H/RS) cells, embryonal carcinoma cells, and on activated T and B lymphocytes. It functions as a receptor for TNFSF8/CD30L and is involved in the regulation of cellular growth and transformation of activated lymphoblasts and regulates signal transduction by activation of NF-κB. Additional information: Clone REA1085 displays negligible binding to Fc receptors. - USA
ABVD - WikipediaABVD - Wikipedia
ABVD is a chemotherapy regimen used in the first-line treatment of Hodgkin lymphoma, supplanting the older MOPP protocol. It consists of concurrent treatment with the chemotherapy drugs: (A)driamycin (also known as doxorubicin/(H)ydroxydaunorubicin, designated as H in CHOP) (B)leomycin (V)inblastine (D)acarbazine (similar to (P)rocarbazine, designated as P in MOPP and in COPP) As of 2007, ABVD is widely used as the initial chemotherapy treatment for newly diagnosed Hodgkins lymphoma.[citation needed] The other chemotherapy regimen that is widely used in this setting is the Stanford V regimen. One cycle of ABVD chemotherapy is typically given over 4 weeks, with two doses in each cycle (on day 1 and day 15). All four of the chemotherapy drugs are given intravenously. ABVD chemotherapy is usually given in the outpatient setting - that is, it does not require hospitalization. Typical dosages for one 28-day cycle of ABVD are as follows: The total number of cycles given depends upon the stage of the ...
Epstein-Barr Virus and Hodgkins Disease: Further Evidence for the Three Disease HypothesisEpstein-Barr Virus and Hodgkin's Disease: Further Evidence for the Three Disease Hypothesis
The epidemiology of Hodgkins disease suggests that it is a heterogeneous condition comprising more than one disease entity. The Epstein-Barr virus (EBV) is present in the Reed-Sternberg cells of a proportion of cases and is likely to play a role in the pathogenesis of these cases. In this study we …
ChemotherapyChemotherapy
Ann Arbor stagingAnn Arbor staging
ABVDABVD
Ann Arbor stagingAnn Arbor staging
Pel-Ebstein feverPel-Ebstein fever
LymphomaLymphoma
Pieter Klazes PelPieter Klazes Pel
Nodular sclerosisNodular sclerosis
MAPK/ERK pathwayMAPK/ERK pathway
Adherence (medicine)Adherence (medicine)
Cancer stagingCancer staging
Carcinogenic bacteriaCarcinogenic bacteria
List of pathologistsList of pathologists
Kim SolezKim Solez
Timeline of lymphomaTimeline of lymphoma
German VillageGerman Village
ToralizumabToralizumab
Michael C. HallMichael C. Hall
Arlen SpecterArlen Specter
Nuclear dotsNuclear dots
Jim VelloneJim Vellone
HD - WikipédiaHD - Wikipédia
LymphocytopeniaLymphocytopenia
Mark Fields (American football)Mark Fields (American football)
Reed-Sternberg cellReed-Sternberg cell
HLA-A1HLA-A1
George CanellosGeorge Canellos
George Siber bibliographyGeorge Siber bibliography
Joe C. Davis Jr.Joe C. Davis Jr.
ThiotepaThiotepa
Computational neuroscienceComputational neuroscience
Pol PotPol Pot
Positron emission tomographyPositron emission tomography
RituximabRituximab
Hematopoietic stem cell transplantationHematopoietic stem cell transplantation
RituximabRituximab
Hyperimmunoglobulin E syndromeHyperimmunoglobulin E syndrome
JC virusJC virus
Order of the Rising SunOrder of the Rising Sun
Category:Cancer - Simple English Wikipedia, the free encyclopediaCategory:Cancer - Simple English Wikipedia, the free encyclopedia
Index of HIV/AIDS-related articlesIndex of HIV/AIDS-related articles
Brain-derived neurotrophic factorBrain-derived neurotrophic factor
John B. Gurdon - WikipédiaJohn B. Gurdon - Wikipédia
ProteasomeProteasome
CD30CD30
Ellis-van Creveld syndromeEllis-van Creveld syndrome
BleomycinBleomycin
NeuroscienceNeuroscience
Robert F. FurchgottRobert F. Furchgott
SIDA, a enciclopedia libreSIDA, a enciclopedia libre
Dale CarnegieDale Carnegie
Radiation therapyRadiation therapy
Development of analogs of thalidomideDevelopment of analogs of thalidomide
Jacobsen syndromeJacobsen syndrome
Lewiston, MaineLewiston, Maine
Eye neoplasmEye neoplasm
Harold E. VarmusHarold E. Varmus
Clwyr ceudod - WicipediaClwy'r ceudod - Wicipedia
आइसीडी-१० अध्याय ब - विकिपीडियाआइसीडी-१० अध्याय ब - विकिपीडिया
David Carr (journalist)David Carr (journalist)
AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesDisciplines and OccupationsAnthropology, Education, Sociology and Social PhenomenaTechnology, Industry, AgricultureInformation ScienceHealth CareGeographicals
Hodgkin DiseaseReed-Sternberg CellsAntigens, CD30MechlorethamineProcarbazineBleomycinVinblastineDacarbazineAntigens, CD20Epstein-Barr Virus InfectionsVincristineLymphomaPrednisoneNeoplasms, Second PrimaryLymph NodesLymphoma, Large B-Cell, DiffuseLymphoma, Non-HodgkinDoxorubicinAntineoplastic Combined Chemotherapy ProtocolsLymphocytesCombined Modality TherapyB-LymphocytesImmunohistochemistrySurvival RateSurvival AnalysisTreatment OutcomeRetrospective StudiesPrognosisFollow-Up StudiesTumor Cells, CulturedTime FactorsHerpesvirus 4, HumanAsparaginaseBostonPrecursor Cell Lymphoblastic Leukemia-LymphomaNational Institute on Aging (U.S.)MedlinePlusGroinAnimal Identification SystemsElectronic MailFood Dispensers, AutomaticEditorial PoliciesAuthorshipPeriodicals as TopicPostal ServiceInternetLymphatic SystemLymphatic VesselsUrogenital NeoplasmsHypermediaAdaptation, PsychologicalResearchInformation SystemsMedical Oncology
Hodgkins Disease | HealthCentralHodgkin's Disease | HealthCentral
Hodgkin Disease | Lymphoma | Hodgkin Lymphoma | MedlinePlusHodgkin Disease | Lymphoma | Hodgkin Lymphoma | MedlinePlus
Remarks on HODGKINS DISEASE | The BMJRemarks on HODGKIN'S DISEASE | The BMJ
What is Hodgkins Disease?What is Hodgkin's Disease?
Changing priorities in Hodgkins disease. | The BMJChanging priorities in Hodgkin's disease. | The BMJ
Hodgkins Disease | OncoLinkHodgkin's Disease | OncoLink
Doctors discover Hodgkins disease has returnedDoctors discover Hodgkin's disease has returned
Will I get Hodgkins disease again?Will I get Hodgkin's disease again?
What is early-stage, unfavorable Hodgkin lymphoma (Hodgkin disease)?What is early-stage, unfavorable Hodgkin lymphoma (Hodgkin disease)?
Hodgkins Disease: Symptoms and Treatment | Newsmax.comHodgkin's Disease: Symptoms and Treatment | Newsmax.com
Hodgkins Disease - Sheila Wyborny - AnobiiHodgkin's Disease - Sheila Wyborny - Anobii
Gonadal function following ABVD therapy for Hodgkins disease. - PubMed - NCBIGonadal function following ABVD therapy for Hodgkin's disease. - PubMed - NCBI
Epidemiology of Hodgkins Disease | Cancer ResearchEpidemiology of Hodgkin's Disease | Cancer Research
Hodgkins disease (1 topics)Hodgkin's disease (1 topics)
Hodgkins Disease | Cancer NetworkHodgkin's Disease | Cancer Network
Gastrointestinal Surgery Clinical - Lymphoma and Hodgkins Disease - Penn SurgeryGastrointestinal Surgery Clinical - Lymphoma and Hodgkin's Disease - Penn Surgery
Hodgkins lymphoma (Hodgkins disease) - Doctors and departments - Mayo ClinicHodgkin's lymphoma (Hodgkin's disease) - Doctors and departments - Mayo Clinic
Hodgkins lymphoma (Hodgkins disease) - Doctors and departments - Mayo ClinicHodgkin's lymphoma (Hodgkin's disease) - Doctors and departments - Mayo Clinic
Hodgkins disease | University of Maryland Medical CenterHodgkin's disease | University of Maryland Medical Center
Actor Michael C. Hall Successful Treatment of Hodgkins Disease by MedicineNet.comActor Michael C. Hall Successful Treatment of Hodgkin's Disease by MedicineNet.com
How is the Stanford V regimen administered in Hodgkin lymphoma (Hodgkin disease)?How is the Stanford V regimen administered in Hodgkin lymphoma (Hodgkin disease)?
Breast cancer in young women after treatment for Hodgkins disease | EurekAlert! Science NewsBreast cancer in young women after treatment for Hodgkin's disease | EurekAlert! Science News
Hodgkins Disease Associations & OrganizationsHodgkin's Disease Associations & Organizations
Lymphoma: Non-Hodgkin | GreenMedInfo | Disease | Natural MedicineLymphoma: Non-Hodgkin | GreenMedInfo | Disease | Natural Medicine
TANOX STARTS TRIAL OF DRUG FOR HODGKINS DISEASETANOX STARTS TRIAL OF DRUG FOR HODGKIN'S DISEASE
Sézary syndrome after successful treatment of Hodgkins disease.Sézary syndrome after successful treatment of Hodgkin's disease.
Abnormal coagulation results in patients with Hodgkins disease.Abnormal coagulation results in patients with Hodgkin's disease.
Hodgkin Disease | CTDHodgkin Disease | CTD
Hodgkin s DiseaseHodgkin s Disease
Concurrent Hodgkins Disease (Mixed Cellularity Type) and T-Cell Chronic Lymphocytic Leukemia/Prolymphocytic Leukemia |...Concurrent Hodgkin's Disease (Mixed Cellularity Type) and T-Cell Chronic Lymphocytic Leukemia/Prolymphocytic Leukemia |...
AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesDisciplines and OccupationsAnthropology, Education, Sociology and Social PhenomenaTechnology, Industry, AgricultureInformation ScienceHealth CareGeographicals
Hodgkin DiseaseReed-Sternberg CellsAntigens, CD30MechlorethamineProcarbazineBleomycinVinblastineDacarbazineAntigens, CD20Epstein-Barr Virus InfectionsVincristineLymphomaPrednisoneNeoplasms, Second PrimaryLymph NodesLymphoma, Large B-Cell, DiffuseLymphoma, Non-HodgkinDoxorubicinAntineoplastic Combined Chemotherapy ProtocolsLymphocytesCombined Modality TherapyB-LymphocytesImmunohistochemistrySurvival RateSurvival AnalysisTreatment OutcomeRetrospective StudiesPrognosisFollow-Up StudiesTumor Cells, CulturedTime FactorsHerpesvirus 4, HumanAsparaginaseBostonPrecursor Cell Lymphoblastic Leukemia-LymphomaNational Institute on Aging (U.S.)MedlinePlusGroinAnimal Identification SystemsElectronic MailFood Dispensers, AutomaticEditorial PoliciesAuthorshipPeriodicals as TopicPostal ServiceInternetLymphatic SystemLymphatic VesselsUrogenital NeoplasmsHypermediaAdaptation, PsychologicalResearchInformation SystemsMedical Oncology
Thomas HodgkinChemotherapyClassical HodgkinLymphomasHodgkin's LymphomaReed-SternbergLymphaticNodular SclerosisPrognosisAdolescentsCancerBiopsyRadiationSymptoms of Hodgkin's diseaseDiagnosis of Hodgkin's diseaseLymphocyte-predominant Hodgkin's diseaseRefractoryTreatmentLymphocytesEpidemiologyCellularityNewly diagnosedMalignant diseaseTeenagersSubtypesSevere coronary arteryCauses of Hodgkin's diseaseAdmitted with Hodgkin's diseaseNLPHLTumorChildhoodCancersPredominantGroinHerpesvirusUncommonCommonlyIncidenceGeneticAffectsRelapseInfectionSigns and SymptomsCause of Hodgkin's disease is unknownChest irradiationOrgansInfectiousMetabolismAbnormalChance of developing HodgkiCells
Thomas Hodgkin5
Chemotherapy37
Classical Hodgkin15
Lymphomas10
Hodgkin's Lymphoma24
Reed-Sternberg14
Lymphatic14
Nodular Sclerosis4
Prognosis3
Adolescents6
Cancer31
Biopsy11
Radiation3
  • They cautioned that the follow-up is too short for long-term effects of radiation -- such as coronary disease or second malignancies -- to affect future survival figures, so that the impact of the therapy may change. (medpagetoday.com)
  • Surgical stagingwith laparotomy (incision through the abdominal wall) and splenectomy (removal of the spleen) are the most accurate means of determining HD spread in patients who show disease above the diaphragm, the large abdominal muscle that controls breathing, and who are candidates for radiation therapy alone. (healthcommunities.com)
  • Clearly, to minimize the risk [for] cardiovascular disease, doses of both radiation to the heart and anthracyclines should be kept as low as possible without jeopardizing the patient's chance of cure. (healio.com)
Symptoms of Hodgkin's disease2
Diagnosis of Hodgkin's disease2
Lymphocyte-predominant Hodgkin's disease5
Refractory5
Treatment26
Lymphocytes4
Epidemiology2
Cellularity1
Newly diagnosed1
Malignant disease1
Teenagers3
Subtypes1
Severe coronary artery1
Causes of Hodgkin's disease2
  • At this time, the cause or causes of Hodgkin's disease are not known, and doctors can seldom explain why one person gets this disease and another does not. (cancercompass.com)
  • The causes of Hodgkin's disease remain incompletely known, but a higher incidence in men than in women has prompted an interest in the role of female sex hormones and reproductive history. (diva-portal.org)
Admitted with Hodgkin's disease1
NLPHL2
Tumor5
  • Abnormal coagulation test results followed the course of disease, normalizing with tumor regression and reappearing during relapse. (biomedsearch.com)
  • In this pivotal single-arm study, one of the largest ever conducted in this patient population, 82% (n=106) of patients, most in their fifth line of therapy or beyond, achieved disease control (defined as stable disease or better) and 74% (n=96) achieved tumor reduction at a median follow-up of 9.6 months, demonstrating the sustained anticancer activity of LBH589. (prnewswire.com)
  • Moreover, the potential pro-apoptotic functions related to Bak and Bax in Hodgkin's disease might be surpassed by a stronger expression of anti-apoptotic molecules thus explaining tumor progression. (nih.gov)
  • Ninety-nine children with Stage IV Hodgkin's disease or Stage IIB/IIIB Hodgkin's disease with bulk disease (presence of a tumor of 6 cm or greater) were enrolled in the study. (nyp.org)
  • The mitogen-activated protein kinase (MAPK) (also called extracellular signal-regulated kinase [ERK]) pathway has been implicated in malignant transformation and in the regulation of cellular growth and proliferation of several tumor types, but its expression and function in Hodgkin disease (HD) are unknown. (bloodjournal.org)
Childhood4
Cancers6
Predominant1
Groin1
Herpesvirus1
Uncommon2
Commonly3
Incidence2
Genetic6
Affects2
  • 3. Hinterberger W, Hinterberger‐Fischer M, Marmont A M. Clinically demonstrable anti‐autoimmunity mediated by allogeneic immune cells favourably affects outcomes after stem cell transplantation in human autoimmune disease. (pubmedcentralcanada.ca)
  • Cardiovascular disease is a widespread issue that affects millions across the world. (labroots.com)
Relapse2
  • PA nobinostat T rial in H odgkin's lymphoma) has begun enrollment, investigating the drug as a maintenance therapy following autologous stem cell transplant in patients with Hodgkin lymphoma who have an increased risk for relapse(6). (prnewswire.com)
  • This is further supported by the results of allogenic HSCT for Crohn's disease, where the only relapse occurred in a patient who developed a mixed donor-host haematopoietic chimerism following allogenic HSCT. (pubmedcentralcanada.ca)
Infection6
Signs and Symptoms1
  • Rapp-Hodgkin syndrome has signs and symptoms that overlap considerably with those of ankyloblepharon-ectodermal defects-cleft lip/palate (AEC) syndrome . (nih.gov)
Cause of Hodgkin's disease is unknown2
Chest irradiation6
Organs3
Infectious5
Metabolism1
Abnormal2
Chance of developing Hodgki2
  • Many would say that you have no more chance of developing Hodgkin's disease in the future than anybody else, and when you consider that the number of new cases diagnosed every year in the UK is about 1500, this is clearly a very small chance indeed. (netdoctor.co.uk)
  • People who are concerned about the chance of developing Hodgkin's disease should talk with their doctor about the disease, the symptoms to watch for, and an appropriate schedule for checkups. (cancercompass.com)
Cells5
Lymphomas 1: Including Hodgkin's Disease, Book by John M. Bennett (Paperback) | chapters.indigo.ca
Lymphomas 1: Including Hodgkin's Disease, Book by John M. Bennett (Paperback) | chapters.indigo.ca (chapters.indigo.ca)
FDA Approved Drugs by Medical Condition | CenterWatch
FDA Approved Drugs by Medical Condition | CenterWatch (centerwatch.com)
Cancer in the HIV-Infected Population - TheBody.com
Cancer in the HIV-Infected Population - TheBody.com (thebody.com)
Erythema Nodosum: Background, Pathophysiology, Etiology
Erythema Nodosum: Background, Pathophysiology, Etiology (emedicine.medscape.com)
Non-Hodgkin's Castleman's disease
Non-Hodgkin's Castleman's disease (netdoctor.co.uk)
Causes of Itching all Over the Body | Livestrong.com
Causes of Itching all Over the Body | Livestrong.com (livestrong.com)
Health advice on HubPages
Health advice on HubPages (hubpages.com)
Will I get Hodgkin's disease again?
Will I get Hodgkin's disease again? (netdoctor.co.uk)
Blog Keyword: Failure to diagnose Hodgkin Disease | Dover Law Firm
Blog Keyword: Failure to diagnose Hodgkin Disease | Dover Law Firm (doverlawfirm.com)
September 1994 - Volume 6 - Issue 5 : Current Opinion in Oncology
September 1994 - Volume 6 - Issue 5 : Current Opinion in Oncology (journals.lww.com)
Judith Peacock | Open Library
Judith Peacock | Open Library (openlibrary.org)
Lymphoma Causes & Risk Factors
Lymphoma Causes & Risk Factors (healthcentral.com)
Long Survival in Hodgkin's Disease. | Annals of Internal Medicine | American College of Physicians
Long Survival in Hodgkin's Disease. | Annals of Internal Medicine | American College of Physicians (annals.org)
Hodgkin Lymphoma Child | Denver Health
Hodgkin Lymphoma Child | Denver Health (denverhealth.org)
Hartl Refused To Give Up On Hope Or Battle - tribunedigital-chicagotribune
Hartl Refused To Give Up On Hope Or Battle - tribunedigital-chicagotribune (articles.chicagotribune.com)
Lymphoma | Lymph Nodes (Glands) Issues discussions | Body & Health Conditions center | SteadyHealth.com
Lymphoma | Lymph Nodes (Glands) Issues discussions | Body & Health Conditions center | SteadyHealth.com (steadyhealth.com)
What is Hodgkin's Disease?
What is Hodgkin's Disease? (news-medical.net)
People - School of Medicine - University of St Andrews
People - School of Medicine - University of St Andrews (st-andrews.ac.uk)
Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Children Aged 6-18...
Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Children Aged 6-18... (cdc.gov)
Intervals Between PCV13 and PPSV23 Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
Intervals Between PCV13 and PPSV23 Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP) (cdc.gov)
Updated Recommendations for Prevention of Invasive Pneumococcal Disease Among Adults Using the 23-Valent Pneumococcal...
Updated Recommendations for Prevention of Invasive Pneumococcal Disease Among Adults Using the 23-Valent Pneumococcal... (cdc.gov)
Alzheimer, Parkinson, Hodgkin: Names of a passing era as naming diseases and conditions after doctors declines | National Post
Alzheimer, Parkinson, Hodgkin: Names of a passing era as naming diseases and conditions after doctors declines | National Post (nationalpost.com)
Orphan Drug Designation Granted for Treatment of Peripheral T-Cell Lymphoma
Orphan Drug Designation Granted for Treatment of Peripheral T-Cell Lymphoma (medindia.net)
Lymphoma Treatment, Causes, Diagnosis & Types
Lymphoma Treatment, Causes, Diagnosis & Types (emedicinehealth.com)
Hodgkin Lymphoma - Hematology and Oncology - Merck Manuals Professional Edition
Hodgkin Lymphoma - Hematology and Oncology - Merck Manuals Professional Edition (merckmanuals.com)
Hodgkin Disease | Lymphoma | Hodgkin Lymphoma | MedlinePlus
Hodgkin Disease | Lymphoma | Hodgkin Lymphoma | MedlinePlus (medlineplus.gov)